Jeffrey Weitz
Professor, Medicine

Dr. Weitz is Professor of Medicine and Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute. Board Certified in Internal Medicine, Hematology and Medical Oncology, Dr. Weitz focuses his clinical practice on patients with thrombotic disorders. His research spans the spectrum from basic studies in the biochemistry of blood coagulation and fibrinolysis to animal models of thrombosis and on to clinical trials of antithrombotic therapy. The breadth of his work is highlighted by his over 500 publications in journals as diverse as the Journal of Clinical Investigation, Journal of Biological Chemistry, Biochemistry, Circulation, Blood, Annals of Internal Medicine, New England Journal of Medicine and Lancet, and 60 book chapters. The recipient of numerous awards, Dr. Weitz is a Fellow of the American Heart Association, the Royal Society of Canada and the Canadian Academy of Health Sciences.

By focusing on the basic mechanisms by which anticoagulants (blood thinners) and thrombolytic agents (clot digesting drugs) work, Dr. Weitz has opened new avenues of investigation. His demonstration that thrombin bound to fibrin is resistant to inactivation by available anticoagulants stimulated the development of new drugs, some of which are already being used in clinical practice. Through other research, Dr. Weitz has provided an explanation for the puzzling clinical observation that the clot digesting drug, tissue-type plasminogen activator or t-PA, produces more bleeding than was originally anticipated. This work has paved the way for new drugs that may be safer than t-PA.

Dr. Weitz is involved in clinical trials examining optimal methods for prevention, diagnosis and treatment of clotting disorders. He also is an active participant in the education of medical students, residents, and postdoctoral fellows. In addition, he coordinates a graduate course in medical sciences and his laboratory is a fertile training ground for graduate students and postdoctoral fellows in medical sciences and bioengineering.

Contact Information

PHONE: 905-574-8550

EMAIL: weitzj

Affiliations

Faculty of Health Sciences, McMaster University
Director, Thrombosis and Atherosclerosis Research Institute (TaARI), Faculty of Health Sciences
Associate Member, Biochemistry & Biomedical Sciences, Faculty of Health Sciences
Professor, Medicine, Faculty of Health Sciences
Canada Research Chair in Thrombosis, McMaster University,

Scholarly Activity in McMaster Experts

Co-author Network

Scholarly Activity
Contact
View All

selected scholarly activity

books
- Hematology 2018
- Preface 2018
- Hematology: Basic Principles and Practice 2012
- New Therapeutic Agents In Thrombosis And Thrombolysis 1997
chapters
- Antiplatelet Drugs in the Management of Venous Thromboembolism, Cardioembolism, Ventricular Assist Devices, and Pregnancy Complications. 1067-1077. 2019
- Acute Coronary Syndromes. 2142-2151.e2. 2018
- Antithrombotic Drugs. 2168-2188. 2018
- Hematologic Problems in the Surgical Patient. 2304-2312.e4. 2018
- Hypercoagulable States. 2076-2087. 2018
- Overview of Hemostasis and Thrombosis. 1831-1842. 2018
- Acute Coronary Syndromes. 2142-2151.e2. 2017
- Antithrombotic Drugs. 2168-2188. 2017
- Hematologic Problems in the Surgical Patient: Bleeding and Thrombosis. 2304-2312.e4. 2017
- Hypercoagulable States. 2076-2087. 2017
- Overview of Hemostasis and Thrombosis. 1831-1842. 2017
- Antiplatelet, Anticoagulant and Fibrinolytic Drugs. 745-760. 2015
- Hemostasis, Thrombosis, Fibrinolysis and Cardiovascular Disease.. 1809-1833. 2014
- Antithrombotic Therapy. 549-566. 2014
- Antiplatelet, Anticoagulant, and Fibrinolytic Drugs. 264-282. 2013
- Pulmonary Embolism. 627-638. 2013
- Venous Thrombosis. 619-626. 2013
- New Antithrombotic Drugs. 1318-1336. 2012
- Acute Coronary Syndromes. 2076-2085. 2012
- Antithrombotic Drugs. 2102-2119. 2012
- Hypercoagulable States. 2013-2024. 2012
- Overview of Hemostasis and Thrombosis. 1774-1783. 2012
- Hemostasis, Thrombosis, Fibrinolysis and Cardiovascular Disease. 1844-1867. 2012
- Antiplatelet, Anticoagulant and Fibrinolytic Drugs. 988-1004. 2011
- Pulmonary Embolism. 596-603. 2011
- Hypercoagulable states.. 521-546. 2011
- Blood Coagulation and Anticoagulant, Fibrinolytic, and Antiplatelet Drugs 2011
- Anticoagulants in Acute Coronary Syndromes.. 232-252. 2010
- Antiplatelet, Anticoagulant, and Fibrinolytic Drugs. 264-282. 2010
- Antithrombotic Agents. 541-555. 2010
- Overview of New Anticoagulant Drugs. 133-154. 2009
- Antithrombotic drugs. 2067-2082. 2008
- Laboratory assessments of platelet function and coagulation.. 19-31. 2008
- Antiplatelet, anticoagulant and fibrinolytic drugs. 735-747. 2008
- Coagulation Overview. 543-553. 2006
- New Antithrombotic Drugs. 1763-1783. 2005
- Anticoagulant and fibrinolytic drugs. 2249-2267. 2005
- Anticoagulant Therapy. 400-417. 2003
- Management of Venous Thrombosis. 511-520. 2003
- Pathogenesis of venous thromboembolism. 39-56. 2003
- Overview of New Anticoagulant Drugs. 61-74. 2002
- Pharmacologic Options for Treatment of Ischemic Heart Disease. 97-153. 2001
- Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. 266-284. 2000
- Laboratory Markers of Coagulation and Fibrinolysis and Their Clinical Application.. 1113-1129. 2000
- New Antithrombotic Drugs. 1529-1544. 2000
- Treatment of Venous Thromboembolism. 218-222. 1999
- Hemostasis and Thrombosis. 246-289. 1998
- Diagnosis and management of peripheral vascular disease. 264-271. 1998
- Antithrombin III, Protein C, and Protein S Deficiency. 882-888. 1997
- Molecular basis for the resistance of fibrin-bound thrombin to inactivation by heparin/serpin complexes. 55-66. 1997
- Overview of new developments in heparins, thrombin inhibitors and other new and novel agents. 77-86. 1997
- Antithrombin Therapy. 9.1-9.14. 1996
- Mechanisms responsible for the increased fibrin-specificity of vampire bat plasminogen activator and its relationship to bleeding 1996
- Antithrombin III, Protein C, and Protein S Deficiency. 201-209. 1995
- Arterial Thromboembolism 1995
- Plasma fibrinopeptide A and B levels may not be specific markers of thrombin activity during pharmacologic thrombolysis. 140-148. 1995
- Venous Thromboembolism. National Medical Journal of India. 193-195. 1995
- Laboratory Markers of Coagulation and Fibrinolysis 1993
- Disseminated intravascular coagulation. 880-884. 1991
- Fibrinolysis 1991
- Mechanism of action of the thrombolytic agents. 583-599. 1990
- Disseminated intravascular coagulation.. 116-119. 1987
conferences
- Management of Edoxaban Therapy in Patients Undergoing Major Surgery: A Sub-Analysis of the Prospective, Observational, Multinational Emit-AF/VTE Study. Blood. 3024-3024. 2021
- COMPARATIVE ASSESSMENT OF ePTFE VASCULAR GRAFT THROMBOGENICITY ON-A-CHIP. MicroTAS 2021 - 25th International Conference on Miniaturized Systems for Chemistry and Life Sciences. 199-200. 2021
- Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study. Blood. 163-163. 2019
- Evaluation of the pharmacodynamics of a ticagrelor reversal agent PB2452. European Heart Journal. 1356-1356. 2019
- COMPARISON OF JNJ9375, A THROMBIN EXOSITE 1-DIRECTED ANTIBODY, WITH APIXABAN FOR THROMBOPROPHYLAXIS AFTER ELECTIVE KNEE REPLACEMENT SURGERY: TEXT-TKR STUDY. Journal of the American College of Cardiology. 2047-2047. 2019
- Medically Ill Patients with Moderate Renal Insufficiency Have More Thrombotic and Bleeding Events Than Those with Normal Renal Function: Insights from the Magellan and Mariner Trials of Extended Thrombprophylaxis. Blood. 1236-1236. 2018
- Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism. Blood. 2527-2527. 2018
- Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research. S223-S223. 2018
- Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research. S194-S194. 2018
- RENAL IMPAIRMENT DOES NOT COMPROMISE DABIGATRAN REVERSAL BY IDARUCIZUMAB. Journal of the American College of Cardiology. A2045-A2045. 2018
- A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study. Blood. 2017
- The Effect of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients with Nonvalvular Atrial Fibrillation. Blood. 2017
- The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients Treated for Venous Thromboembolism. Blood. 2017
- The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in the Prevention of Venous Thromboembolism after Elective Hip or Knee Replacement Surgery. Blood. 2017
- Idarucizumab in Dabigatran-Treated Patients Requiring Emergency Surgery or Intervention: Updated/Final Results From the RE-VERSE AD Study. Circulation. 2017
- The effect of rivaroxaban exposure and clinical risk factors on efficacy and safety outcomes in patients with acute coronary syndromes. Journal of Pharmacokinetics and Pharmacodynamics. S59-S59. 2017
- Lifestyle risk factors for non-valvular atrial fibrillation. European Heart Journal. 239-239. 2017
- New onset dementia in incident atrial fibrillation. A large cohort study. European Heart Journal. 983-983. 2017
- DEVELOPMENT OF A SCREENING AND DIAGNOSTIC ALGORITHM FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA USING A MODIFIED DELPHI PANEL METHODOLOGY. Haematologica. 224-225. 2017
- Lys 42, 43, 44 and Arg 12 of Thrombin Activable Fibrinolysis Inhibitor Comprise Thrombomodulin Binding Exosite Essential for Exerting Its Antifibrinolytic Activity. Arteriosclerosis, Thrombosis and Vascular Biology. 2017
- Idarucizumab For Dabigatran Reversal: Updated Results Of The Re-verse Ad Study. Circulation. E714-E715. 2016
- Comparison of locally measured activated partial thromboplastin time (aPTT) to central laboratory aPTT when measuring reversal of dabigatran using idarucizumab. Journal of Thrombosis and Haemostasis. 30-30. 2016
- 792 Do Concurrent Gastroprotective Agents Impact Gastrointestinal Bleeding Rates in Edoxaban Users? Results From the ENGAGE-AF TIMI 48 Trial. Gastroenterology. S165-S165. 2016
- HEALTH CARE RESOURCE UTILIZATION IN PATIENTS REQUIRING URGENT SURGICAL/INTERVENTIONAL MANAGEMENT WHILE TAKING DABIGATRAN: INTERIM RESULTS FROM THE RE-VERSE AD STUDY. Journal of the American College of Cardiology. 669-669. 2016
- IDARUCIZUMAB FOR REVERSAL OF THE ANTICOAGULANT EFFECTS OF DABIGATRAN IN PATIENTS IN AN EMERGENCY SETTING OF MAJOR BLEEDING, URGENT SURGERY, OR INTERVENTIONS. Journal of the American College of Cardiology. 664-664. 2016
- Idarucizumab reversal of anticoagulation in dabigatran-treated patients presenting with acute traumatic injuries: Interim results from the RE-VERSE AD Study. British Journal of Haematology. 11-11. 2016
- RECURRENT VENOUS THROMBOEMBOLISM IN PULMONARY EMBOLISM PATIENTS WITH RIGHT VENTRICULAR DYSFUNCTION IN THE HOKUSAI-VTE STUDY. Journal of the American College of Cardiology. 2061-2061. 2016
- Effect of Idarucizumab on Intracranial Bleeding in Dabigatran-treated Patients: Initial Results From REVERSE AD.. Stroke. 2016
- Initial experience with idarucizumab in dabigatran-treated patients requiring emergency surgery or interventon: interim results from the RE-VERSE AD study. European Heart Journal. 1043-1043. 2015
- A novel substrate for use in a point of care thrombin generation assay. Journal of Thrombosis and Haemostasis. 211-211. 2015
- An open-label study of dabigatran pharmacokinetics and pharmacodynamics in patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery. Journal of Thrombosis and Haemostasis. 643-644. 2015
- Apixaban for treatment of venous thromboembolism in patients from study centres in Asia; a subgroup analysis of the amplify trial. Journal of Thrombosis and Haemostasis. 727-727. 2015
- Arterial thrombosis is accelerated in histidine-rich glycoprotein deficient mice. Journal of Thrombosis and Haemostasis. 204-205. 2015
- Cell-Free DNA modulates clot structure and impairs fibrinolysis in sepsis. Journal of Thrombosis and Haemostasis. 341-341. 2015
- Clinical presentation and extent of clinical care of clinically relevant non-major bleeding events with apixaban and warfarin. Journal of Thrombosis and Haemostasis. 900-900. 2015
- Clinical presentation, impact and course of major bleeding events with apixaban and warfarin. Journal of Thrombosis and Haemostasis. 635-636. 2015
- Comparison of the effect of dabigatran and warfarin on mechanical heart valve-induced thrombin generation. Journal of Thrombosis and Haemostasis. 115-115. 2015
- DNA and RNA activate the contact pathway of coagulation by promoting reciprocal activation of factor XII and prekallikrein. Journal of Thrombosis and Haemostasis. 206-206. 2015
- Engagement of the active site of thrombin by dabigatran or argatroban modulates its exosite-mediated interactions with fibrin and factor VA. Journal of Thrombosis and Haemostasis. 312-312. 2015
- Histidine-rich glycoprotein binds DNA and RNA and attenuates their capacity to activate the intrinsic pathway of coagulation. Journal of Thrombosis and Haemostasis. 569-570. 2015
- Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions. Journal of Thrombosis and Haemostasis. 85-85. 2015
- Intrinsic and extrinsic coagulation pathways both contribute to ligation-induced deep vein thrombosis in rats. Journal of Thrombosis and Haemostasis. 78-78. 2015
- Localization of ZN2+in dense granules of human platelets and the extent of its release upon platelet activation. Journal of Thrombosis and Haemostasis. 407-407. 2015
- Lysine residues 42, 43, and 44 of thrombin activable fibrinolysis inhibitor contribute to its activation by the thrombin-thrombomodulin complex in a cooperative fashion. Journal of Thrombosis and Haemostasis. 264-264. 2015
- Proteolytic inactivation of coagulation factor V by OmpT from enterohemorrhagic Escherichia coli. Journal of Thrombosis and Haemostasis. 311-311. 2015
- Rivaroxaban associates with factor Xa faster than apixaban: a potential explanation for their different effects on tests of coagulation. Journal of Thrombosis and Haemostasis. 556-556. 2015
- Twice-daily dosing of ASA overcomes reduced platelet response to once-daily ASA after coronary artery bypass graft surgery: a randomized controlled trial. Journal of Thrombosis and Haemostasis. 928-929. 2015
- ZN(2+) accelerates clot formation, modifies clot structure, and promotes clot stability. Journal of Thrombosis and Haemostasis. 56-56. 2015
- PERIOPERATIVE ADVERSE OUTCOMES IN PATIENTS WITH ATRIAL FIBRILLATION TAKING EDOXABAN OR WARFARIN: ANALYSIS OF THE ENGAGE AF-TIMI 48 TRIAL. Journal of the American College of Cardiology. A2092-A2092. 2015
- Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis. Blood. 2014
- Time in Therapeutic Range (TTR) and Relative Efficacy and Safety of Treatment with Apixaban or Enoxaparin/Warfarin for Acute Symptomatic Venous Thromboembolism: An Analysis of the Amplify Trial Data. Blood. 2014
- Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. European Heart Journal. 190-190. 2014
- Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. European Heart Journal. 994-994. 2014
- Time course of recurrent venous thromboembolic and major bleeding events during anticoagulant therapy with apixaban or enoxaparin/warfarin: analysis of the amplify data using landmark method. Journal of Thrombosis and Haemostasis. 18-18. 2014
- Edoxaban For Long-Term Treatment Of Venous Thromboembolism In Cancer Patients. Blood. 211-211. 2013
- Randomized trial to examine the effect of ASA dose or ASA dosing frequency on ASA resistance after coronary artery bypass graft surgery. European Heart Journal. 22-23. 2013
- Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis. 18-18. 2013
- Clots formed from y '-fibrinogen are more resistant to lysis than those formed from? A-fibrinogen because of delayed plasminogen activation by tissue plasminogen activator. Journal of Thrombosis and Haemostasis. 304-304. 2013
- DNA and RNA promote kallikrein-mediated activation of fXII and are cofactors for fXI feedback activation by thrombin. Journal of Thrombosis and Haemostasis. 429-429. 2013
- Effects of three-factor and four-factor prothrombin complex concentrates on the pharmacodynamics of rivaroxaban. Journal of Thrombosis and Haemostasis. 167-167. 2013
- Histidine-rich glycoprotein binds to DNA, RNA and fXIIa with high affinity and attenuates contact-mediated coagulation in a mouse model of arterial thrombosis. Journal of Thrombosis and Haemostasis. 20-20. 2013
- Plasma fibronectin supports hemostasis, controls the diameter of fibrin fibers, and regulates thrombosis. Journal of Thrombosis and Haemostasis. 36-37. 2013
- Prothrombin activation intermediates bind thrombomodulin demonstrating sequential capacitation of exosite 1. Journal of Thrombosis and Haemostasis. 193-193. 2013
- Selective depletion of contact factors with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Journal of Thrombosis and Haemostasis. 20-20. 2013
- Zinc inhibits fibrinolysis by attenuating plasminogen activation and fibrin degradation. Journal of Thrombosis and Haemostasis. 793-793. 2013
- Two Doses of Apixaban for the Extended Treatment of Venous Thromboembolism. Blood. 2012
- 504 Subtle Differences in Commercial Heparins Can Have Serious Consequences for Cardiopulmonary Bypass Patients: a randomized controlled trial. Canadian Journal of Cardiology. S285-S285. 2012
- Kringle domains of plasmin are essential for efficient degradation of fibrin but not fibrinogen. Journal of Thrombosis and Haemostasis. E23-E23. 2012
- Extended Anticoagulant Prophylaxis in Initially Hospitalized Medically Ill Patients: Results of the ADOPT (Apixaban Dosing to Optimize Protection from Thrombosis) Trial. Circulation. 2366-2366. 2011
- Batroxobin and thrombin bind to distinct sites on fibrinogen and fibrin. Journal of Thrombosis and Haemostasis. 374-374. 2011
- Catheter thrombosis with fondaparinux is prevented by thrombin inhibition in vitro and in rabbits. Journal of Thrombosis and Haemostasis. 566-566. 2011
- Corn trypsin inhibitor coating attenuates the prothrombotic properties of coronary catheters in vitro and in rabbits. Journal of Thrombosis and Haemostasis. 811-812. 2011
- Diannexin, a homodimer of annexin A5 (A5), binds phosphatidylserine (PS) with high affinity and is a potent inhibitor of arterial thrombosis in mice. Journal of Thrombosis and Haemostasis. 727-727. 2011
- High affinity binding of plasminogen to fibrin is not essential for efficient activation by tissue plasminogen activator. Journal of Thrombosis and Haemostasis. 847-847. 2011
- Histidine-rich glycoprotein binds fibrinogen with high affinity and modulates thrombin binding to the gamma '-chain. Journal of Thrombosis and Haemostasis. 759-759. 2011
- When assembled into their respective activation complexes, factors Xa, IXa, and VIIa are differentially protected from inhibition by the antithrombin/heparin complex. Journal of Thrombosis and Haemostasis. 277-278. 2011
- Zn2+ delays Glu-and Lys-plasminogen activation by tissue plasminogen activator and inhibits plasmin activity toward macromolecular substrates. Journal of Thrombosis and Haemostasis. 849-849. 2011
- AHA2010 Antithrombotic therapy in atherosclerosis. Therapeutic Research. 129-133. 2011
- Clots formed from gamma '-fibrinogen are resistant to lysis because of impaired plasminogen activation by t-PA. Journal of Thrombosis and Haemostasis. 6-6. 2010
- PCV110 COST-EFFECTIVENESS ANALYSIS OF ENOXAPARIN FOR EXTENDED THROMBOPROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) AFTER ELECTIVE TOTAL HIP REPLACEMENT (THR) SURGERY. Value in Health. A333-A333. 2009
- New approaches to oral anticoagulation: Direct thrombin inhibitors. Thrombosis and Haemostasis. 11-15. 2009
- Randomized, Parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b Compared with Warfarin in Subjects with Non-Valvular Atrial Fibrillation. Blood. 18-18. 2008
- Randomized double-blind multi-dose trial of the oral factor-Xa inhibitor DU-176b versus LMW Heparin (Dalteparin) for prevention of venous thromboembolism after total hip replacement. European Heart Journal. 609-609. 2008
- Zinc enhances the protection of fibrin-bound thrombin from antithrombin inhibition. Blood. 790A-791A. 2007
- Factor Xa or thrombin: Is thrombin a better target?. Journal of Thrombosis and Haemostasis. 65-67. 2007
- Factor V Binding to Multimerin 1: Modulation by Factor V Activation and Binding Sites in the Factor V C1 and C2 Domains.. Blood. 193-193. 2006
- We-W40:1 New anticoagulants for atherothrombosis. Atherosclerosis Plus. 324-325. 2006
- Thrombin Aptamer HD1 Inhibits Prothrombin Activation by Binding Proexosite 1 on Prothrombin.. Blood. 1950-1950. 2005
- Zinc2+ Promotes Heparin Binding to Fibrin and Subsequent Formation of Ternary Heparin-Thrombin-Fibrin Complexes.. Blood. 1956-1956. 2005
- New anticoagulants. Journal of Thrombosis and Haemostasis. 1843-1853. 2005
- Non-anticoagulant fondaparinux retains anti-inflammatory activity in a mouse model of kidney ischemia-reperfusion injury. Arteriosclerosis, Thrombosis and Vascular Biology. E53-E53. 2005
- No fibrinolytic benefit of adjunctive anticoagulation during arterial thrombolysis induced by tPA combined with TAFIa inhibitor in a rabbit arterial thrombosis model.. Blood. 813A-813A. 2004
- Role of Plasminogen-Fibrin Interaction in Plasminogen Activation by t-PA.. Blood. 1737-1737. 2004
- Role of Thrombin Exosites in Protection from Inhibition by Antithrombin in the Presence of Heparin and Fibrin.. Blood. 1721-1721. 2004
- Studies into the Mechanism by Which Glycosaminoglycans Potentiate Protein C Activation by Factor Xa.. Blood. 1724-1724. 2004
- Cofactor role of fibrin in stimulation of tissue-type plasminogen activation of Glu- and Mini-plasminogen.. Blood. 304A-304A. 2003
- Efficacy and safety of combining dalteparin with aspirin in preventing venous thromboembolism in medical patients.. Blood. 321A-321A. 2003
- FIXa incorporated within intrinsic tenase is protected from inhibition by ATIII/heparin complex.. Blood. 305A-305A. 2003
- Mortality is increased in patients with proximal, but not distal, deep vein thrombosis in medically ill patients entered in the PREVENT trial.. Blood. 165A-166A. 2003
- Venous ultrasound: An alternative to venography for evaluation of Dalteparin prophylaxis in 3,706 medically ill hospitalized patients.. Blood. 324A-325A. 2003
- Novel antithrombotic drug reduces arterial Doppler high intensity transient signals during and after hypothermic cardiopulmonary bypass in pigs. Circulation. 433-433. 2003
- GH9001, a novel antithrombotic agent, is more effective than low-molecular-weight heparin or hirudin in rabbit models.. Blood. 83A-83A. 2002
- Heparin catalysis of factor IXa inhibition by antithrombin depends on both pentasaccharide-induced conformational changes in antithrombin and heparin-mediated bridging of antithrombin to factor IXa.. Blood. 264A-264A. 2002
- Low-intensity (INR 1.5-1.9) versus conventional-intensity (INR 2.0-3.0) anticoagulation for extended treatment of unprovoked VTE: A randomized double blind trial.. Blood. 150A-150A. 2002
- New antithrombins. REPORTS FROM THE 17TH INTERNATIONAL CONGRESS ON THROMBOSIS. 139-144. 2002
- Preoperative chemoradiation of rectal cancer reduces the detection rate of disseminated cancer cells in blood and bone marrow. Annals of Surgical Oncology. S13-S14. 2002
- Both exosites on thrombin mediate its high affinity interaction with fibrin.. Blood. 530A-530A. 2001
- Covalent antithrombin-heparin complex (ATH): An alternative to heparin for arterial thrombosis prevention.. Blood. 48A-48A. 2001
- Four weeks versus 12 weeks of anticoagulation for a first episode of venous thromboembolism (VTE) provoked by a transient-risk factor: A randomized double-blind trial.. Blood. 448A-448A. 2001
- In vitro comparison of the effect of heparin, low-molecular-weight heparin and pentasaccharide on tests of coagulation.. Blood. 45A-45A. 2001
- Melagatran, the active form of the oral direct thrombin inhibitor ximelagatran - An alternative to hirudin in prevention of arterial thrombosis with a wider therapeutic window.. Blood. 41A-42A. 2001
- Role of the B beta 1-42 sequence of fibrin(ogen) in plasminogen activation.. Blood. 255A-255A. 2001
- The thrombin-specific anticoagulant, bivalirudin, completely inhibits thrombin-mediated platelet aggregation.. American Journal of Cardiology. 83G-83G. 2001
- Fibrinogen gamma chain binds thrombin exosite II.. Blood. 448A-449A. 2000
- Identification of the mechanism responsible for the decreased fibrin specificity of reteplase relative to tissue-type plasminogen activator.. Blood. 47A-47A. 2000
- Incorporation of fragment X into clots increases their susceptibility to lysis.. Blood. 44A-44A. 2000
- Phospholipid micelles, but not vesicles, neutralize heparin: An explanation for the minimal effect of heparin on the prothrombin time.. Blood. 45A-45A. 2000
- Metabolic and hematological effects of ramipril in the HOPE trial. Circulation. 408-408. 2000
- Randomized comparison of vasoflux, a novel anticoagulant, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction. European Heart Journal. 187-187. 2000
- Randomized comparison of vasoflux, a novel anticoagulant, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction. Journal of the American College of Cardiology. 373A-373A. 2000
- Calcium-dependent binding of heparin influences the catalytic activity of factor Xa.. Blood. 91B-91B. 1999
- Homocysteine enhances cholesterol biosynthesis in cultured human smooth muscle cells and hepatocytes.. Blood. 449A-449A. 1999
- Impact of size-restricted diffusion of thbombin inhibitors into thrombi on the susceptibility of fibrin-bound thrombin to inactivation.. Blood. 22A-23A. 1999
- Potential interaction of bivalirudin and heparin after interchange of these agents.. Blood. 114B-114B. 1999
- The effect of heparin on bone strength in mice.. Blood. 21A-21A. 1999
- The glycosylation site within kringle 1 modulates fibrin-specificity of TNK-t-PA.. Blood. 232A-232A. 1999
- The safety and efficacy of a TAFIa inhibitor ln a rabbit arterial thrombolysis and bleeding model.. Blood. 22A-22A. 1999
- Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) in unstable angina (USA) and Non-Q-Wave myocardial infarction (NQMI): A mete-analysis. Circulation. 621-621. 1999
- Evidence that change in the kringle-1 glycosylation site contributes to the increased fibrin-specificity of TNK-t-PA relative to t-PA. Thrombosis and Haemostasis. 708-708. 1999
- Evidence that unfractionated heparin and low molecular weight heparin are eliminated by tubular secretion in the rat kidney. Thrombosis and Haemostasis. 32-32. 1999
- Functional analysis of exosites 1 and 2 of thrombin in complex with serine protease inhibitors. Thrombosis and Haemostasis. 698-698. 1999
- New antithrombotic drugs: Beyond aspirin and heparin - Chairman's summary. Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 68-68. 1999
- Heparin-induced bone loss is not reversible after stopping heparin treatment in rats.. Blood. 358A-358A. 1998
- Inhibition of angiogenesis in a fibrin matrix by abciximab.. Blood. 173A-173A. 1998
- Investigation of the anticoagulant mechanisms of a covalent antithrombin-heparin complex.. Blood. 358A-358A. 1998
- Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor II in the presence of dermatan sulfate, but not heparin.. Blood. 552A-552A. 1998
- The effect of heparin and low molecular weight heparin on osteoblastogenesis in vitro.. Blood. 358A-358A. 1998
- Vitronectin mediates the high affinity binding of plasminogen activator inhibitor-1 to fibrin.. Blood. 550A-550A. 1998
- V20, a glycoprotein IIb/IIIa-independent inhibitor of platelet-dependent clotting reactions, inhibits both arterial and venous-type thrombosis in primates. Circulation. 800-800. 1998
- Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. American Journal of Cardiology. 12P-18P. 1998
- Sulphated low molecular weight heparin is a potent inhibitor of intrinsic tenase and prothrombinase.. British Journal of Haematology. 68-68. 1998
- The clinical pharmacology of Vasoflux (TM) compared to heparin, results of a phase I clinical trial. XIII WORLD CONGRESS OF CARDIOLOGY. 1045-1049. 1998
- The pharmacokinetics and pharmacodynamics of Vasoflux (TM), results of a phase I clinical trial. XIII WORLD CONGRESS OF CARDIOLOGY. 1041-1044. 1998
- Both thrombin exosites are required to form a ternary thrombin-heparin-fibrin complex that attenuates thrombin inhibition.. Blood. 122-122. 1997
- Differential expression and synthesis of GRP78 and HSP70 by homocysteine.. Blood. 1265-1265. 1997
- Heparin binds to tissue factor: An explanation for heparin's limited effect on the prothrombin time.. Blood. 1290-1290. 1997
- Homocysteine alters mitochondrial gene expression, function and structure.. Blood. 1358-1358. 1997
- Mutations in the glycosaminoglycan-binding domain of heparin cofactor II result in variants with increased thrombin inhibitory activity.. Blood. 120-120. 1997
- Sulfated low molecular weight heparin is a potent inhibitor of intrinsic tenase and prothrombinase.. Blood. 116-116. 1997
- The fibrin-specificities of tissue-type plasminogen activator and, to a lesser extent, the TNK variant are compromised by kringle-dependent interactions with (DD)E.. Blood. 633-633. 1997
- Vasoflux, a novel anticoagulant that is more effective than heparin and safer than hirudin in rabbits.. Blood. 1316-1316. 1997
- Clinical evaluation of the pharmacology, and safety of Vasoflux(TM), a novel antithrombotic. Circulation. 216-216. 1997
- Identification of a unique glomerular factor X activator in murine lupus nephritis.. Journal of the American Society of Nephrology. A2240-A2240. 1997
- A novel antithrombin-heparin covalent complex: Efficacy and safety in rabbits. Thrombosis and Haemostasis. P2812-P2812. 1997
- Both thrombin exosites are required to form a thrombin-heparin-fibrin complex that attenuates thrombin inhibition. Thrombosis and Haemostasis. P1741-P1741. 1997
- Diagnosis of a first dvt in outpatients: Interim analysis of a management based on clinical evaluation and D-dimer (SimpliRED(TM)) results. Thrombosis and Haemostasis. O2400-O2400. 1997
- Evidence for allosteric linkage of exosites 1 and 2 of thrombin. Thrombosis and Haemostasis. P1740-P1740. 1997
- Localization of the thrombin-binding domain on prothrombin fragment 2. Thrombosis and Haemostasis. P1736-P1736. 1997
- Mechanism of tissue plasminogen activator-induced increase in fibrinopeptide A levels in rabbits. Thrombosis and Haemostasis. OC778-OC778. 1997
- New antithrombotic strategies: Lessens from clinical trials with glycoprotein IIb/IIIa antagonists and direct thrombin inhibitors. International Journal of Clinical Practice, Supplement. 25-35. 1997
- Plasmin generated on the (DD)E surface is protected from inactivation by alpha(2)-antiplasmin. Thrombosis and Haemostasis. P1465-P1465. 1997
- Prothrombin fragment 2 modulates thrombin function. Thrombosis and Haemostasis. P1752-P1752. 1997
- The fibrin-specificity of plasminogen activators is compromised by their interactions with (DD)E. Thrombosis and Haemostasis. OC779-OC779. 1997
- Vasoflux(TM), a novel oligosaccharide with unique antithrombotic properties. Thrombosis and Haemostasis. P2831-P2831. 1997
- Thrombin and factor XIIa generation in plasma contacting polyurethane surfaces: Effect of surface immobilized PPACK. Transactions of the Annual Meeting of the Society for Biomaterials in conjunction with the International Biomaterials Symposium. 709. 1996
- The value of the SimpliRed(R) D-dimer in a prospective management study of patients with suspected pulmonary embolism (PE).. Blood. 137-137. 1996
- Use of a clinical model in a prospective management study of patients with suspected pulmonary embolism (PE).. Blood. 2490-2490. 1996
- Hirudin (HBW-023) suppresses markers of coagulation more effectively than heparin. Circulation. 4070-4070. 1996
- Characterization of the interactions of lys-plasminogen and tissue and vampire bat plasminogen activators with fibrin and (DD)E.. Blood. 1133-1133. 1995
- Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding. Journal of Vascular and Interventional Radiology. S19-S23. 1995
- EVIDENCE FOR REBOUND ACTIVATION OF THE COAGULATION SYSTEM AFTER CESSATION OF INTRAVENOUS ANTICOAGULANT-THERAPY FOR ACUTE MYOCARDIAL-ISCHEMIA. Circulation. 2314-2314. 1995
- ANTITHROMBOTIC THERAPY IN PATIENTS UNDERGOING CORONARY ANGIOPLASTY. Chest. S486-S501. 1995
- NEW ANTITHROMBOTICS. Chest. S471-S485. 1995
- BAT PLASMINOGEN-ACTIVATOR CAUSES LESS FIBRINOGENOLYSIS AND BLEEDING THAN TISSUE-PLASMINOGEN ACTIVATOR IN RATS. Thrombosis and Haemostasis. 1339-1339. 1995
- FIBRIN CLOT LYSIS BY TISSUE-PLASMINOGEN ACTIVATOR (TPA) IS IMPAIRED IN PLASMA FROM PEDIATRIC-PATIENTS UNDERGOING ORTHOTOPIC LIVER-TRANSPLANTATION. Thrombosis and Haemostasis. 1329-1329. 1995
- HIRUDIN, BUT NOT HEPARIN, ACCELERATES PHYSIOLOGICAL FIBRINOLYSIS IN A RABBIT CHRONIC VENOUS THROMBOSIS MODEL. Thrombosis and Haemostasis. 1454-1454. 1995
- THE EFFECT OF ANTITHROMBIN-III AND HEPARIN COFACTOR-II CONCENTRATIONS ON THE ANTICOAGULANT ACTIVITIES OF STANDARD AND LOW-MOLECULAR-WEIGHT HEPARIN IN PLASMA. Thrombosis and Haemostasis. 935-935. 1995
- THE EFFECT OF HEPARIN-BINDING PROTEINS ON THE ANTI-THROMBIN ACTIVITY OF UNFRACTIONATED AND LOW-MOLECULAR-WEIGHT HEPARIN IN PLASMA. Thrombosis and Haemostasis. 973-973. 1995
- ANISOYLATED STREPTOKINASE-PLASMINOGEN ACTIVATOR COMPLEX OFFERS NO ADVANTAGE OVER STREPTOKINASE FOR FIBRIN CLOT LYSIS IN CORD PLASMA. Pediatric Research. A283-A283. 1995
- ABNORMALITIES IN FIBRINOLYSIS PREDICT FOR RECURRENT DEEP-VEIN THROMBOSIS. Blood. A69-A69. 1994
- A NOVEL INHIBITOR OF THROMBIN CONTAINING MULTIPLE RECOGNITION SEQUENCES LINKED BY A ALPHA-KETO AMIDE TRANSITION-STATE MIMETIC. Circulation. 348-348. 1994
- STIMULATION OF TPA-MEDIATED PLASMINOGEN ACTIVATION BY PHYSIOLOGICAL FIBRIN DEGRADATION PRODUCTS. Circulation. 619-619. 1994
- DIRECT CLEAVAGE OF COAGULATION FACTOR-X BY GLOMERULI FROM MICE WITH SPONTANEOUS LUPUS NEPHRITIS. Journal of the American Society of Nephrology. 743-743. 1994
- A COMPARISON OF THE PLASMA RECOVERY OF UNFRACTIONATED HEPARIN WITH THAT OF DERMATAN SULFATE IN PATIENTS WITH THROMBOEMBOLIC DISEASE. Thrombosis and Haemostasis. 657-657. 1993
- A RANDOMIZED TRIAL COMPARING THE ACTIVATED THROMBOPLASTIN TIME WITH THE HEPARIN ASSAY TO MONITOR HEPARIN-THERAPY IN PATIENTS WITH ACUTE VENOUS THROMBOEMBOLISM REQUIRING LARGE DAILY DOSES OF HEPARIN. Thrombosis and Haemostasis. 1122-1122. 1993
- CLOT-BOUND THROMBIN IS PROTECTED FROM INACTIVATION BECAUSE THE SITES OF ANTIPROTEINASE INTERACTION WITH THROMBIN ARE MASKED WHEN THE ENZYME IS BOUND TO FIBRIN. Thrombosis and Haemostasis. 894-894. 1993
- EVIDENCE FOR THE GENERATION OF ELASTASE ACTIVITY IN A PRIMATE MODEL OF DISSEMINATED INTRAVASCULAR COAGULATION (DIC). Thrombosis and Haemostasis. 1127-1127. 1993
- INCREASED THROMBIN GENERATION AND ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS (SLE) AND ANTICARDIOLIPIN ANTIBODIES (ACA) - EVIDENCE FOR A PROTHROMBOTIC STATE. Thrombosis and Haemostasis. 954-954. 1993
- OPTIMAL DURATION OF ORAL ANTICOAGULANT-THERAPY - A RANDOMIZED TRIAL COMPARING 4 WEEKS WITH 3 MONTHS OF WARFARIN IN PATIENTS WITH PROXIMAL DEEP-VEIN THROMBOSIS (DVT). Thrombosis and Haemostasis. 982-982. 1993
- THE COMBINATION OF PRETEST CLINICAL LIKELIHOOD (PCL) AND NONINVASIVE TESTS IMPROVES MANAGEMENT OF OUTPATIENTS WITH SUSPECTED DEEP-VEIN THROMBOSIS (DVT). Thrombosis and Haemostasis. 1080-1080. 1993
- THE POTENTIATION OF FIBRIN POLYMERIZATION BY TISSUE-PLASMINOGEN ACTIVATOR (TPA). Thrombosis and Haemostasis. 1259-1259. 1993
- THE ROLE OF (DD)E IN THE KINETICS OF PLASMINOGEN ACTIVATION BY TISSUE-PLASMINOGEN ACTIVATOR. Thrombosis and Haemostasis. 544-544. 1993
- ZONES OF ADHESION FORMED BETWEEN PLATELETS AND MATRIX PROTEINS. Thrombosis and Haemostasis. 567-567. 1993
- ALPHA-2-ANTIPLASMIN SUPPLEMENTATION INHIBITS TISSUE PLASMINOGEN-ACTIVATOR INDUCED FIBRINOGENOLYSIS AND BLEEDING WITH LITTLE EFFECT ON THROMBOLYSIS. Clinical Research. A194-A194. 1993
- SUSTAINED ANTITHROMBOTIC ACTIVITY OF HIRUDIN AFTER ITS PLASMA-CLEARANCE - COMPARISON WITH HEPARIN. Thrombosis Research. S16-S16. 1993
- A PHASE-II STUDY OF HIRULOG IN THE PREVENTION OF VENOUS THROMBOSIS AFTER MAJOR HIP OR KNEE SURGERY. Circulation. 409-409. 1992
- ALPHA-2-ANTIPLASMIN INHIBITS TISSUE PLASMINOGEN-ACTIVATOR INDUCED FIBRINOGENOLYSIS AND BLEEDING WITHOUT AFFECTING THROMBOLYSIS. Circulation. 149-149. 1992
- MECHANISM BY WHICH CLOT-BOUND THROMBIN IS PROTECTED FROM INACTIVATION BY FLUID-PHASE INHIBITORS. Circulation. 413-413. 1992
- THE EFFECT OF PLASMA-PROTEINS ON THE ANTI-IIA AND ANTI-XA ACTIVITIES OF STANDARD HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN. Circulation. 869-869. 1992
- PLATELETS FORM PROTECTED COMPARTMENTS WITH FIBRINOGEN AND FIBRONECTIN-COATED SURFACES. Molecular Biology of the Cell. A75-A75. 1992
- ALPHA-2-ANTIPLASMIN SUPPLEMENTATION SELECTIVELY INHIBITS TISSUE PLASMINOGEN ACTIVATOR-INDUCED FIBRINOGENOLYSIS WITHOUT AFFECTING CLOT LYSIS. Thrombosis and Haemostasis. 1094-1094. 1991
- COMPARISON OF ANTITHROMBIN ACTIVITIES OF HEPARIN AND HIRULOG-1 - BASIS FOR IMPROVED ANTITHROMBOTIC PROPERTIES OF DIRECT THROMBIN INHIBITORS. Thrombosis and Haemostasis. 829-829. 1991
- DO COAGULATION SCREENING-TESTS DETECT INCREASED GENERATION OF THROMBIN AND PLASMIN IN SICK NEWBORN-INFANTS. Thrombosis and Haemostasis. 720-720. 1991
- HEPARIN INHIBITS THE AMPLIFICATION OF COAGULATION MEDIATED BY CLOT-BOUND THROMBIN. Thrombosis and Haemostasis. 759-759. 1991
- IMPAIRED FIBRINOLYTIC-ACTIVITY AND RECURRENT VENOUS THROMBOEMBOLIC DISEASE. Thrombosis and Haemostasis. 979-979. 1991
- PLATELET-INDUCED CLOT RETRACTION INHIBITS STREPTOKINASE BUT NOT TISSUE PLASMINOGEN-ACTIVATOR MEDIATED CLOT LYSIS. Thrombosis and Haemostasis. 718-718. 1991
- POSTOPERATIVE-PATIENT PLASMA INDUCES ENDOTHELIAL-CELL TYPE-I PLASMINOGEN-ACTIVATOR INHIBITOR SYNTHESIS. Thrombosis and Haemostasis. 1274-1274. 1991
- THE EFFECT OF THROMBIN INHIBITORS ON TISSUE PLASMINOGEN ACTIVATOR-INDUCED THROMBOLYSIS IN A RAT MODEL. Thrombosis and Haemostasis. 735-735. 1991
- THE RATE OF FIBRINOPEPTIDE-B RELEASE MODULATES THE RATE OF CLOT FORMATION - A STUDY WITH AN ACQUIRED INHIBITOR TO FIBRINOPEPTIDE-B RELEASE. Thrombosis and Haemostasis. 1020-1020. 1991
- THROMBIN REMAINS BOUND TO SOLUBLE FIBRIN DEGRADATION PRODUCTS AND IS PARTIALLY PROTECTED FROM INHIBITION BY HEPARIN-ANTITHROMBIN .3.. Thrombosis and Haemostasis. 931-931. 1991
- PLATELET-INDUCED CLOT RETRACTION INHIBITS STREPTOKINASE (SK) BUT NOT TISSUE PLASMINOGEN-ACTIVATOR (T-PA) MEDIATED CLOT LYSIS. Circulation. 375-375. 1990
- SOLUBLE FIBRIN DEGRADATION PRODUCTS POTENTIATE TISSUE PLASMINOGEN-ACTIVATOR (T-PA) INDUCED FIBRINOGENOLYSIS. Circulation. 600-600. 1990
- CLOT-BOUND THROMBIN IS PROTECTED FROM INHIBITION BY DERMATAN SULFATE-HEPARIN COFACTOR-II. Arteriosclerosis. A927-A927. 1990
- PLATELET-INDUCED CLOT RETRACTION INHIBITS STREPTOKINASE (SK) BUT NOT TISSUE PLASMINOGEN-ACTIVATOR (T-PA) MEDIATED CLOT LYSIS. Arteriosclerosis. A901-A902. 1990
- SOLUBLE FIBRIN DEGRADATION PRODUCTS POTENTIATE TISSUE PLASMINOGEN-ACTIVATOR (T-PA) INDUCED FIBRINOGENOLYSIS. Arteriosclerosis. A908-A909. 1990
- COAGULATION SCREENING-TESTS DETECT INCREASED GENERATION OF THROMBIN AND PLASMIN IN SICK NEWBORN-INFANTS. Pediatric Research. A268-A268. 1990
- THROMBIN FORMATION IS INCREASED IN SEVERE NEONATAL RESPIRATORY-DISTRESS SYNDROME (RDS). Pediatric Research. A224-A224. 1990
- FIBRIN CLOT LYSIS BY THROMBOLYTIC AGENTS IS IMPAIRED IN THE NEWBORN. Thrombosis and Haemostasis. 288-288. 1989
- FIBRINOGENOLYSIS IS AN INEVITABLE CONSEQUENCE OF TISSUE PLASMINOGEN-ACTIVATOR MEDIATED CLOT LYSIS. Arteriosclerosis. A694-A694. 1988
- UROKINASE RELEASES FIBRINOPEPTIDE-B FROM FIBRINOGEN AND RENDERS IT LESS CLOTTABLE BY THROMBIN. Arteriosclerosis. A701-A701. 1988
- HUMAN TISSUE-TYPE PLASMINOGEN-ACTIVATOR RELEASES FIBRINOPEPTIDE-A AND FIBRINOPEPTIDE-B FROM FIBRINOGEN. Clinical Research. A422-A422. 1988
- IDENTIFICATION OF A NEUTROPHIL ELASTASE CLEAVAGE SITE ON THE A-ALPHA-CHAIN OF PRIMATE FIBRINOGEN. Thrombosis and Haemostasis. 300-300. 1987
- CIGARETTE-SMOKING INCREASES INVIVO NEUTROPHIL ELASTASE ACTIVITY. Clinical Research. A540-A540. 1987
- HUMAN NEUTROPHIL ELASTASE-MEDIATED FIBRINOGENOLYSIS DURING BLOOD-COAGULATION. Clinical Research. A436-A436. 1987
- HUMAN NEUTROPHIL ELASTASE-MEDIATED FIBRINOGENOLYSIS DURING BLOOD-COAGULATION. Clinical and Investigative Medicine. B83-B83. 1987
- NEUTROPHIL (PMN)-MEDIATED FIBRINOGEN PROTEOLYSIS IN THE PRESENCE OF PROTEINASE-INHIBITORS. Circulation. 94-94. 1986
- COMPLICATIONS OF LONG-TERM ANTICOAGULATION. Annals of Neurology. 156-156. 1986
- HUMAN-LEUKOCYTE ELASTASE ACTIVITY IN NEONATAL RESPIRATORY-DISTRESS SYNDROME. Pediatric Research. A426-A426. 1986
- INCREASED SYSTEMIC ELASTOLYTIC ACTIVITY IN CHRONIC LUNG-DISEASES. Clinical Research. A694-A694. 1986
- EFFECTS OF INTERMITTENT PNEUMATIC CALF COMPRESSION ON POSTOPERATIVE THROMBIN AND PLASMIN ACTION. Thrombosis and Haemostasis. 98-98. 1985
- EVIDENCE FOR SIMULTANEOUS CLEAVAGE OF THE A-ALPHA-CHAIN AND B-BETA-CHAINS IN THE EARLY STAGES OF PLASMIN DIGESTION OF FIBRINOGEN. Thrombosis and Haemostasis. 47-47. 1985
- IDENTIFICATION OF A SPECIFIC LEUKOCYTE ELASTASE CLEAVAGE SITE ON THE FIBRINOGEN A-ALPHA-CHAIN. Thrombosis and Haemostasis. 47-47. 1985
- UNIQUE CLEAVAGE OF FIBRINOGEN BY HUMAN-LEUKOCYTE ELASTASE. Thrombosis and Haemostasis. 39-39. 1985
- RELATIONSHIP BETWEEN CLEAVAGE OF THE A-ALPHA-CHAIN AND THE B-BETA-CHAIN DURING THE EARLY STAGES OF PLASMIN DIGESTION OF FIBRINOGEN. The FASEB Journal. 776-776. 1984
- FIBRIN PROTEOLYSIS AND PLATELET ALPHA-GRANULE RELEASE IN PRE-ECLAMPSIA AND ECLAMPSIA. Thrombosis and Haemostasis. 322-322. 1983
journal articles
- Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design.. American Heart Journal. 277:145-158. 2024
- International Clinical Practice Guideline Recommendations for Acute Pulmonary Embolism: Harmony, Dissonance, and Silence.. Journal of the American College of Cardiology. 84:1561-1577. 2024
- Arterial Thrombosis: Present and Future.. Circulation. 150:905-907. 2024
- Antithrombotic Strategies for Patients With Peripheral Artery Disease: JACC Scientific Statement.. Journal of the American College of Cardiology. 84:936-952. 2024
- Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper. Thrombosis and Haemostasis. 124:770-777. 2024
- Histidine-Rich Glycoprotein Modulates the Toxic Effects of High-Dose Polyphosphate in Mice. Arteriosclerosis, Thrombosis and Vascular Biology. 44:1658-1670. 2024
- Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 22:2889-2899. 2024
- Current Gaps in the Provision of Safe and Effective Anticoagulation in Atrial Fibrillation and the Potential for Factor XI-Directed Therapeutics. Critical Pathways in Cardiology. 23:47-57. 2024
- Global Health Burden of Venous Thromboembolism. Arteriosclerosis, Thrombosis and Vascular Biology. 44:1007-1011. 2024
- Optimization of plasma-based BioID identifies plasminogen as a ligand of ADAMTS13. Scientific Reports. 14:9073. 2024
- Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial. Nature Medicine. 30:435-442. 2024
- Direct Oral Anticoagulation Versus Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves: a Retrospective, Real-World Cohort Study. Cardiovascular Drugs and Therapy. 38:109-117. 2024
- Human platelets contain a pool of free zinc in dense granules. Research and Practice in Thrombosis and Haemostasis. 8:102352-102352. 2024
- Thrombin-activatable fibrinolysis inhibitor and sex modulate thrombus stability and pulmonary embolism burden in a murine model. Journal of Thrombosis and Haemostasis. 22:263-270. 2024
- When Direct Oral Anticoagulants Should Not Be Standard Treatment. Journal of the American College of Cardiology. 83:444-465. 2024
- PAR4 Inhibition Reduces Coronary Artery Atherosclerosis and Myocardial Fibrosis in SR-B1/LDLR Double Knockout Mice. Arteriosclerosis, Thrombosis and Vascular Biology. 43:2165-2178. 2023
- Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis. Stroke. 54:2724-2736. 2023
- Warfarin faring better: vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials. Journal of Thrombosis and Haemostasis. 21:3067-3071. 2023
- New Therapeutic Targets for the Prevention and Treatment of Venous Thromboembolism With a Focus on Factor XI Inhibitors. Arteriosclerosis, Thrombosis and Vascular Biology. 43:1755-1763. 2023
- Histidine-rich glycoprotein attenuates catheter thrombosis. Blood Advances. 7:5651-5660. 2023
- Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction. Oncologist. 28:555-564. 2023
- News at XI: moving beyond factor Xa inhibitors. Journal of Thrombosis and Haemostasis. 21:1692-1702. 2023
- Reversal agents for current and forthcoming direct oral anticoagulants. European Heart Journal. 44:1795-1806. 2023
- Recommendation on the nomenclature for anticoagulants: updated communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Commitee on the Control of Anticoagulation. Journal of Thrombosis and Haemostasis. 21:1381-1384. 2023
- Direct Oral Anticoagulants in the Very Elderly. Thrombosis and Haemostasis. 123:377-379. 2023
- 36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE. Thrombosis Research. 222:31-39. 2023
- Allosteric modulation of exosite 1 attenuates polyphosphate-catalyzed activation of factor XI by thrombin. Journal of Thrombosis and Haemostasis. 21:83-93. 2023
- Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro. Journal of Thrombosis and Haemostasis. 21:76-82. 2023
- What Is the Future of Factor XI Inhibitors?. Circulation. 146:1899-1902. 2022
- Highly Stable Hierarchically Structured All-Polymeric Lubricant-Infused Films Prevent Thrombosis and Repel Multidrug-Resistant Pathogens. ACS Applied Materials & Interfaces. 14:53535-53545. 2022
- Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors. RMD Open. 8:e002571-e002571. 2022
- Challenges facing early career women in thrombosis and hemostasis—meeting the needs of the next generation. Journal of Thrombosis and Haemostasis. 20:2453-2455. 2022
- Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness. Journal of the American Heart Association. 11:e026229. 2022
- A Vascular Graft On‐a‐Chip Platform for Assessing the Thrombogenicity of Vascular Prosthesis and Coatings with Tuneable Flow and Surface Conditions. Advanced Functional Materials. 32. 2022
- Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. 8:695-706. 2022
- Corrigendum to “Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE” [Thromb. Res. 2020 Jul; 191:103–112]. Thrombosis Research. 216:129-129. 2022
- State-of-the-Art Mini Review: Dual-Pathway Inhibition to Reduce Arterial and Venous Thromboembolism. Thrombosis and Haemostasis. 122:1279-1287. 2022
- Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. JAMA cardiology. 7:747-747. 2022
- ISTH Biennial Impact Report: Looking back and looking forward. Journal of Thrombosis and Haemostasis. 20:1515-1517. 2022
- Long-Term Risk of Major Bleeding after Discontinuing Anticoagulation for Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis. Thrombosis and Haemostasis. 122:1186-1197. 2022
- Fibrous hydrogels under biaxial confinement. Nature Communications. 13:3264. 2022
- Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. Circulation. 145:1471-1479. 2022
- Identification of the histidine‐rich glycoprotein domains responsible for contact pathway inhibition. Journal of Thrombosis and Haemostasis. 20:821-832. 2022
- Transparent and Highly Flexible Hierarchically Structured Polydimethylsiloxane Surfaces Suppress Bacterial Attachment and Thrombosis Under Static and Dynamic Conditions. Small. 18:e2108112. 2022
- Ciraparantag as a potential universal anticoagulant reversal agent. European Heart Journal. 43:993-995. 2022
- Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD‐VTE. Journal of Thrombosis and Haemostasis. 20:366-374. 2022
- Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRD. Kidney International Reports. 7:200-209. 2022
- Producing Fluorine- and Lubricant-Free Flexible Pathogen- and Blood-Repellent Surfaces Using Polysiloxane-Based Hierarchical Structures. ACS Applied Materials & Interfaces. 14:3864-3874. 2022
- Corrigendum to “Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE” [Thromb. Res. 2021 May;201:63–72]. Thrombosis Research. 209:105-105. 2022
- Trends in the proportion of women as reviewers, editors, and editorial board members of 15 North American and British medical journals from 2014 to 2019: A retrospective study. European Science Editing. 48. 2022
- Milvexian for the Prevention of Venous Thromboembolism. New England Journal of Medicine. 385:2161-2172. 2021
- The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood. 138:2173-2184. 2021
- Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. Kidney International. 100:1199-1207. 2021
- Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19. JAMA Internal Medicine. 181:1612-1612. 2021
- Immunothrombosis Biomarkers for Distinguishing Coronavirus Disease 2019 Patients From Noncoronavirus Disease Septic Patients With Pneumonia and for Predicting ICU Mortality. Critical Care Explorations. 3:e0588-e0588. 2021
- Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD‐VTE. Journal of Thrombosis and Haemostasis. 19:3031-3043. 2021
- Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. Journal of Thrombosis and Haemostasis. 19:3008-3017. 2021
- Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial. Thrombosis and Haemostasis. 121:1684-1695. 2021
- Use of novel antithrombotic agents for COVID‐19: Systematic summary of ongoing randomized controlled trials. Journal of Thrombosis and Haemostasis. 19:3080-3089. 2021
- Abelacimab for Prevention of Venous Thromboembolism. New England Journal of Medicine. 385:1821-1823. 2021
- In pregnant women with suspected VTE and low/intermediate or unlikely pretest probability, D-dimer rules out VTE at 3 mo. ACP journal club. 174:JC130-JC130. 2021
- Long‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta‐analysis. Journal of Thrombosis and Haemostasis. 19:2801-2813. 2021
- Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. Journal of Thrombosis and Haemostasis. 19:2772-2780. 2021
- Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism. ACP journal club. 174:1420-1429. 2021
- Polyphosphate-induced thrombosis in mice is factor XII dependent and is attenuated by histidine-rich glycoprotein. Blood Advances. 5:3540-3551. 2021
- Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery. Annals of Surgery. 274:e204-e211. 2021
- Abelacimab for Prevention of Venous Thromboembolism. New England Journal of Medicine. 385:609-617. 2021
- Factor XI Inhibition to Uncouple Thrombosis From Hemostasis. Journal of the American College of Cardiology. 78:625-631. 2021
- International Society on Thrombosis and Haemostasis: Present and future. Journal of Thrombosis and Haemostasis. 19:1599-1601. 2021
- The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE. Thrombosis Research. 203:155-162. 2021
- Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID‐19: A single‐center prospective longitudinal study. Journal of Thrombosis and Haemostasis. 19:1546-1557. 2021
- Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE. Thrombosis Research. 201:63-72. 2021
- Factor XI as a Target for New Anticoagulants. Hamostaseologie. 41:104-110. 2021
- Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19. Journal of the American College of Cardiology. 77:1903-1921. 2021
- Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients. Journal of the American Heart Association. 10:e019459. 2021
- Polysiloxane Nanofilaments Infused with Silicone Oil Prevent Bacterial Adhesion and Suppress Thrombosis on Intranasal Splints. ACS Biomaterial Science and Engineering. 7:541-552. 2021
- Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin. Research and Practice in Thrombosis and Haemostasis. 5:308-313. 2021
- Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE. Research and Practice in Thrombosis and Haemostasis. 5:326-341. 2021
- New anticoagulants: Moving beyond the direct oral anticoagulants. Journal of Thrombosis and Haemostasis. 19:20-29. 2021
- Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management. Critical Reviews in Oncology/Hematology. 157:103125-103125. 2021
- Hypercoagulability and coronavirus disease 2019–associated hypoxemic respiratory failure: Mechanisms and emerging management paradigms. Journal of Trauma and Acute Care Surgery. 89:e177-e181. 2020
- Single and multi-functional coating strategies for enhancing the biocompatibility and tissue integration of blood-contacting medical implants. Clinical Materials. 258:120291-120291. 2020
- Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease. JAMA network open. 3:e2022886-e2022886. 2020
- Obituary for Dr. Clive Kearon. Journal of Thrombosis and Haemostasis. 18:2783-2784. 2020
- Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood. 136:1433-1441. 2020
- Activated thrombin‐activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin‐dependent plasmin generation on thrombin‐activated platelets. Journal of Thrombosis and Haemostasis. 18:2364-2376. 2020
- Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. Journal of Thrombosis and Thrombolysis. 50:267-277. 2020
- Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence. Thrombosis and Haemostasis. 120:1147-1158. 2020
- Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve–Induced Thrombin Generation. Annals of Thoracic Surgery. 110:582-590. 2020
- COVID-19 coagulopathy, thrombosis, and bleeding. Blood. 136:381-383. 2020
- Hospitalized COVID-19 Patients and Venous Thromboembolism. Circulation. 142:129-132. 2020
- Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation. Journal of Thrombosis and Thrombolysis. 50:20-29. 2020
- Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism. Journal of Thrombosis and Thrombolysis. 50:12-19. 2020
- Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism. Journal of Thrombosis and Thrombolysis. 50:1-11. 2020
- Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. Thrombosis Research. 191:103-112. 2020
- Corrigendum to “Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study” [Thromb. Res. vol. 185, January 2020, pages 13–19]. Thrombosis Research. 191:156-159. 2020
- Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: Systematic review and meta‐analysis. Journal of Thrombosis and Haemostasis. 18:1661-1671. 2020
- Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thrombosis and Haemostasis. 120:1004-1024. 2020
- Call to Action to Prevent Venous Thromboembolism in Hospitalized Patients: A Policy Statement From the American Heart Association. Circulation. 141:e914-e931. 2020
- COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. Journal of the American College of Cardiology. 75:2950-2973. 2020
- Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. Journal of the American College of Cardiology. 75:3140-3147. 2020
- The contact activation system as a potential therapeutic target in patients with COVID‐19. Research and Practice in Thrombosis and Haemostasis. 4:500-505. 2020
- Therapeutic strategies for thrombosis: new targets and approaches. Nature Reviews Drug Discovery. 19:333-352. 2020
- Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer. Thrombosis and Haemostasis. 120:847-856. 2020
- Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nature Reviews Cardiology. 17:242-257. 2020
- Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials. Thrombosis and Haemostasis. 120:515-524. 2020
- Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal. 55:1901697-1901697. 2020
- Novel antithrombotic strategies for treatment of venous thromboembolism. Blood. 135:351-359. 2020
- Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty. Journal of the American Medical Association (JAMA). 323:130-130. 2020
- Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment. Thrombosis and Haemostasis. 120:014-026. 2020
- Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study. Thrombosis Research. 185:13-19. 2020
- Recent advances in understanding, diagnosing and treating venous thrombosis. F1000Research. 9:1206-1206. 2020
- Biofunctional Lubricant-Infused Vascular Grafts Functionalized with Silanized Bio-Inks Suppress Thrombin Generation and Promote Endothelialization. ACS Biomaterial Science and Engineering. 5:6485-6496. 2019
- Lubricant‐Infused PET Grafts with Built‐In Biofunctional Nanoprobes Attenuate Thrombin Generation and Promote Targeted Binding of Cells. Small. 15:e1905562. 2019
- Randomized phase 2 trial comparing JNJ‐9375, a thrombin‐directed antibody, with apixaban for prevention of venous thrombosis. Journal of Thrombosis and Haemostasis. 17:2081-2088. 2019
- Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition. Thrombosis Research. 184:44-49. 2019
- Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post‐hoc analysis of the Hokusai‐VTE Cancer study. Journal of Thrombosis and Haemostasis. 17:1866-1874. 2019
- Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD‐VTE patients. Journal of Thrombosis and Haemostasis. 17:1694-1706. 2019
- Are Ticks the Answer to Medical Device-Associated Clotting?. Journal of the American College of Cardiology. 74:2190-2192. 2019
- Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment. Journal of the American College of Cardiology. 74:1760-1768. 2019
- Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study. Hematology Journal. 104:e474-e477. 2019
- Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry. Thrombosis and Haemostasis. 119:1675-1685. 2019
- Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. New England Journal of Medicine. 381:585-586. 2019
- Mortality Risk Profiles for Sepsis: A Novel Longitudinal and Multivariable Approach. Critical Care Explorations. 1:e0032-e0032. 2019
- The blood compatibility challenge. Part 1: Blood-contacting medical devices: The scope of the problem. Acta Biomaterialia. 94:2-10. 2019
- Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. Thrombosis and Haemostasis. 119:1365-1372. 2019
- Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. The BMJ. 366:l4363-l4363. 2019
- Illustrated State‐of‐the‐Art Capsules of the ISTH 2019 Congress in Melbourne, Australia. Research and Practice in Thrombosis and Haemostasis. 3:431-497. 2019
- Response by Chan and Weitz to Letter Regarding Article, “Antithrombotic Agents: New Directions in Antithrombotic Therapy”. Circulation Research. 124:e119. 2019
- Factor XIII Prevents Pulmonary Emboli in Mice by Stabilizing Deep Vein Thrombi. Thrombosis and Haemostasis. 119:992-999. 2019
- Incident Atrial Fibrillation, Dementia and the Role of Anticoagulation: A Population-Based Cohort Study. Thrombosis and Haemostasis. 119:981-991. 2019
- Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. New England Journal of Medicine. 380:1825-1833. 2019
- Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials. Thrombosis and Haemostasis. 119:689-694. 2019
- Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. Circulation. 139:2170-2185. 2019
- AB023, A Novel Antibody That Binds Factor XI and Blocks Its Activation by Factor XIIa. Arteriosclerosis, Thrombosis and Vascular Biology. 39:533-535. 2019
- MAA868 locks factor XIa in a zymogen-like state. Blood. 133:1393-1394. 2019
- Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis. 119:461-466. 2019
- Rivaroxaban for Prevention and Treatment of Venous Thromboembolism. Future Cardiology. 15:63-77. 2019
- Identification and characterization of a factor Va-binding site on human prothrombin fragment 2. Scientific Reports. 9:2436. 2019
- Antithrombotic Agents. Circulation Research. 124:426-436. 2019
- Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. Thrombosis and Haemostasis. 119:319-327. 2019
- Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis. Circulation Research. 124:351-353. 2019
- Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. Circulation Research. 124:416-425. 2019
- Advances in Antithrombotic Therapy. Arteriosclerosis, Thrombosis and Vascular Biology. 39:7-12. 2019
- Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome. Therapeutic Advances in Cardiovascular Disease. 13:175394471986364-175394471986364. 2019
- The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations. Thrombosis and Haemostasis. 119:014-038. 2019
- Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients. Blood Advances. 2:3193-3195. 2018
- Lubricant-Infused Surfaces with Built-In Functional Biomolecules Exhibit Simultaneous Repellency and Tunable Cell Adhesion. ACS Nano. 12:10890-10902. 2018
- Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial. Circulation. 138:1963-1973. 2018
- Effect of Different Doses of Acetylsalicylic Acid on the Antithrombotic Activity of Clopidogrel in a Mouse Arterial Thrombosis Model. Arteriosclerosis, Thrombosis and Vascular Biology. 38:2338-2344. 2018
- Fibrinolysis: strategies to enhance the treatment of acute ischemic stroke. Journal of Thrombosis and Haemostasis. 16:1932-1940. 2018
- The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. Thrombosis Research. 170:75-83. 2018
- Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. New England Journal of Medicine. 379:1118-1127. 2018
- Conductive Electrochemically Active Lubricant‐Infused Nanostructured Surfaces Attenuate Coagulation and Enable Friction‐Less Droplet Manipulation. Advanced Materials Interfaces. 5. 2018
- Establishing Therapeutic Equivalence of Complex Pharmaceuticals: The Case of Dabigatran. Canadian Journal of Cardiology. 34:1116-1119. 2018
- Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. Thrombosis Research. 168:121-129. 2018
- Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. Thrombosis and Haemostasis. 118:1439-1449. 2018
- Antiplatelet therapy in the management of atherothrombosis: recent clinical advances. Blood Advances. 2:1806-1806. 2018
- Screening and diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria: Expert consensus. European Journal of Haematology. 101:3-11. 2018
- Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. New England Journal of Medicine. 378:2191-2201. 2018
- Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with bioprosthetic valves. Expert Review of Cardiovascular Therapy. 16:413-418. 2018
- Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. Journal of Stroke and Cerebrovascular Diseases. 27:1673-1682. 2018
- Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial. Thrombosis and Haemostasis. 118:1001-1008. 2018
- Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. Blood. 131:2151-2160. 2018
- Gastrointestinal Bleeding With Edoxaban Versus Warfarin. Circulation. Cardiovascular Quality and Outcomes. 11:e003998. 2018
- Reversal agents for non-vitamin K antagonist oral anticoagulants. Nature Reviews Cardiology. 15:273-281. 2018
- Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies. Thrombosis and Haemostasis. 118:S23-S33. 2018
- Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Advances. 2:788-796. 2018
- Addressing the burden of hospital‐related venous thromboembolism: the role of extended anticoagulant prophylaxis. Journal of Thrombosis and Haemostasis. 16:413-417. 2018
- Erratum. Journal of Thrombosis and Haemostasis. 16:609-609. 2018
- Expert Consensus Guidelines for Stocking of Antidotes in Hospitals That Provide Emergency Care. Annals of Emergency Medicine. 71:314-325.e1. 2018
- Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. New England Journal of Medicine. 378:615-624. 2018
- 2017 Scientific Sessions Sol Sherry Distinguished Lecture in Thrombosis. Arteriosclerosis, Thrombosis and Vascular Biology. 38:304-310. 2018
- Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research. 162:7-14. 2018
- Global public awareness about atrial fibrillation. Research and Practice in Thrombosis and Haemostasis. 2:49-57. 2018
- Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers. Journal of Thrombosis and Haemostasis. 16:54-64. 2018
- Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations. Journal of Thrombosis and Haemostasis. 15:2377-2387. 2017
- Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. Thrombosis and Haemostasis. 117:2406-2414. 2017
- A Test in Context: D-Dimer. Journal of the American College of Cardiology. 70:2411-2420. 2017
- Dabigatran Reversal with Idarucizumab. New England Journal of Medicine. 377:1690-1692. 2017
- Dabigatran Reversal with Idarucizumab.. New England Journal of Medicine. 377:1691-1692. 2017
- An omniphobic lubricant-infused coating produced by chemical vapor deposition of hydrophobic organosilanes attenuates clotting on catheter surfaces. Scientific Reports. 7:11639. 2017
- In high-risk patients with arthritis and previous upper GI bleeding, celecoxib vs naproxen reduced recurrent bleeding. ACP journal club. 167:JC17-JC17. 2017
- Idarucizumab for Dabigatran Reversal — Full Cohort Analysis. New England Journal of Medicine. 377:431-441. 2017
- Impact of World Thrombosis Day campaign. Research and Practice in Thrombosis and Haemostasis. 1:138-141. 2017
- Research and Practice in Thrombosis and Haemostasis – a new ISTH publishing platform for the global thrombosis and hemostasis community. Research and Practice in Thrombosis and Haemostasis. 1:6-8. 2017
- Extended Treatment of Venous Thromboembolism. New England Journal of Medicine. 376:2491-2492. 2017
- Extended Treatment of Venous Thromboembolism REPLY. New England Journal of Medicine. 376:2492-2492. 2017
- Exosite 2-Directed Ligands Attenuate Protein C Activation by the Thrombin–Thrombomodulin Complex. Biochemistry. 56:3119-3128. 2017
- Evaluation of direct oral anticoagulants in superficial-vein thrombosis – Authors' reply. The Lancet Haematology. 4:e254-e255. 2017
- Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa. Scientific Reports. 7:2102. 2017
- Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study. Journal of Medical Economics. 20:435-442. 2017
- Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents. Stroke. 48:1432-1437. 2017
- Anticoagulation for Mechanical Heart Valves. Arteriosclerosis, Thrombosis and Vascular Biology. 37:743-745. 2017
- Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation. JAMA cardiology. 2:566-566. 2017
- Once versus twice daily aspirin after coronary bypass surgery: a randomized trial. Journal of Thrombosis and Haemostasis. 15:889-896. 2017
- Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. New England Journal of Medicine. 376:1211-1222. 2017
- Platelet polyphosphate: the long and the short of it. Blood. 129:1574-1575. 2017
- Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. The Lancet Haematology. 4:e105-e113. 2017
- Reversal of Direct Oral Anticoagulants: Current Status and Future Directions. Seminars in Respiratory and Critical Care Medicine. 38:040-050. 2017
- Emerging anticoagulant strategies. Blood. 129:147-154. 2017
- Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. Thrombosis Research. 149:29-37. 2017
- Factors XI and XII as Targets for New Anticoagulants. Frontiers in Medicine. 4:19. 2017
- Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential. Thrombosis and Haemostasis. 117:1509-1517. 2017
- Measuring Dabigatran Levels: What Tests Are Available and What Still Needs to Be Done?. Thrombosis and Haemostasis. 117:2213-2214. 2017
- New developments in anticoagulants: Past, present and future. Thrombosis and Haemostasis. 117:1283-1288. 2017
- Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants. F1000Research. 6:985-985. 2017
- Prosthetic Heart Valve Thrombosis. Journal of the American College of Cardiology. 68:2671-2689. 2016
- Prosthetic Heart Valve Thrombosis. Journal of the American College of Cardiology. 68:2670-2689. 2016
- Response by Weitz and Eikelboom to Letter Regarding Article, “Urgent Need to Measure Effects of Direct Oral Anticoagulants”. Circulation. 134:e498. 2016
- A PoTENtial Antidote. Circulation Research. 119:1157-1160. 2016
- A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk Score. Canadian Journal of Cardiology. 32:1332-1339. 2016
- Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis. 116:1159-1164. 2016
- Global Anticoagulant Registry in the Field – Venous Thromboembolism (GARFIELD-VTE). Thrombosis and Haemostasis. 116:1172-1179. 2016
- Venous thromboembolism: A Call for risk assessment in all hospitalised patients. Thrombosis and Haemostasis. 116:777-779. 2016
- Ciraparantag for enoxaparin reversal: Adding to the evidence. Thrombosis Research. 146:106-107. 2016
- D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment. Thrombosis Research. 146:119-125. 2016
- Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. The Lancet. 388:1995-2003. 2016
- Idarucizumab for dabigatran overdose. Clinical Toxicology. 54:644-646. 2016
- Optimizing the safety of treatment for venous thromboembolism in the era of the direct oral anticoagulants. Polskie Archiwum Medycyny Wewnetrznej. 126:688-696. 2016
- Appropriate Apixaban Dosing. JAMA cardiology. 1:635-635. 2016
- Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. The Lancet Haematology. 3:e437-e445. 2016
- Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. European Stroke Journal. 1:146-154. 2016
- An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150 mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery. Thrombosis Research. 144:158-164. 2016
- Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. The Lancet Haematology. 3:e379-e387. 2016
- Urgent Need to Measure Effects of Direct Oral Anticoagulants. Circulation. 134:186-188. 2016
- NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank. American Heart Journal. 177:74-86. 2016
- Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. The Lancet Haematology. 3:e228-e236. 2016
- Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. The Lancet Haematology. 3:E228-E236. 2016
- Factor XI and factor XII as targets for new anticoagulants. Thrombosis Research. 141:S40-S45. 2016
- North American Thrombosis Forum, AF Action Initiative Consensus Document. American Journal of Medicine. 129:S1-S29. 2016
- Advances in Thrombosis and Hemostasis. Circulation Research. 118:1337-1339. 2016
- Evolving Treatments for Arterial and Venous Thrombosis. Circulation Research. 118:1409-1424. 2016
- Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation. Thrombosis and Haemostasis. 115:257-270. 2016
- Rapid quantitative D‐dimer to exclude pulmonary embolism: a prospective cohort management study. Journal of Thrombosis and Haemostasis. 14:504-509. 2016
- When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 14:623-627. 2016
- A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. Thrombosis and Haemostasis. 116:241-250. 2016
- Activation of protein C and thrombin activable fibrinolysis inhibitor on cultured human endothelial cells. Journal of Thrombosis and Haemostasis. 14:366-374. 2016
- Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function. PLoS ONE. 11:e0157471-e0157471. 2016
- Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. Thrombosis and Haemostasis. 116:747-753. 2016
- Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. Thrombosis and Haemostasis. 115:809-816. 2016
- Histidine-rich glycoprotein binds DNA and RNA and attenuates their capacity to activate the intrinsic coagulation pathway. Thrombosis and Haemostasis. 115:89-98. 2016
- Letter to the Editor. Journal of Intensive Care Medicine. 31:70-71. 2016
- Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease. Thrombosis and Haemostasis. 115:685-711. 2016
- Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials. Thrombosis and Haemostasis. 116:S33-S40. 2016
- The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Thrombosis and Haemostasis. 115:1240-1248. 2016
- Zinc promotes clot stability by accelerating clot formation and modifying fibrin structure. Thrombosis and Haemostasis. 115:533-542. 2016
- Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis. Arteriosclerosis, Thrombosis and Vascular Biology. 35:2544-2553. 2015
- Idarucizumab. Circulation. 132:2412-2422. 2015
- Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis. 13:2187-2191. 2015
- Free intraperitoneal tumor cells and outcome in gastric cancer patients: a systematic review and meta-analysis. Oncotarget. 6:35564-35578. 2015
- Binding of anti-GRP78 autoantibodies to cell surface GRP78 increases tissue factor procoagulant activity via the release of calcium from endoplasmic reticulum stores.. Journal of Biological Chemistry. 290:28725-28725. 2015
- Trends in Prescribing Oral Anticoagulants in Canada, 2008–2014. Clinical Therapeutics. 37:2506-2514.e4. 2015
- Zinc delays clot lysis by attenuating plasminogen activation and plasmin-mediated fibrin degradation. Thrombosis and Haemostasis. 113:1278-1288. 2015
- ‘Real world’ use of non-vitamin K antagonist oral anticoagulants (NOACs): Lessons from the Dresden NOAC Registry. Thrombosis and Haemostasis. 113:1159-1161. 2015
- Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) and post thrombotic syndrome (PTS). Thrombosis Research. 136:S13-S18. 2015
- Timing the First Postoperative Dose of Anticoagulants. Chest. 148:587-595. 2015
- Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve‐Induced Thrombin Generation. Journal of the American Heart Association. 4:e002322. 2015
- Idarucizumab for Dabigatran Reversal. New England Journal of Medicine. 373:511-520. 2015
- Delayed but not Early Treatment with DNase Reduces Organ Damage and Improves Outcome in a Murine Model of Sepsis. Shock. 44:166-172. 2015
- Global public awareness of venous thromboembolism. Journal of Thrombosis and Haemostasis. 13:1365-1371. 2015
- Medical device‐induced thrombosis: what causes it and how can we prevent it?. Journal of Thrombosis and Haemostasis. 13:S72-S81. 2015
- Novel oral anticoagulants and reversal agents: Considerations for clinical development. American Heart Journal. 169:751-757. 2015
- Venous thrombosis. Nature Reviews Disease Primers. 1:15006. 2015
- Overview of the New Oral Anticoagulants. Arteriosclerosis, Thrombosis and Vascular Biology. 35:1056-1065. 2015
- Arterial thrombosis is accelerated in mice deficient in histidine-rich glycoprotein. Blood. 125:2712-2719. 2015
- Factor XI Antisense Oligonucleotide for Venous Thrombosis. New England Journal of Medicine. 372:1671-1672. 2015
- Anticoagulation therapy in 2015: where we are and where we are going. Journal of Thrombosis and Thrombolysis. 39:264-272. 2015
- Active metabolite concentration of clopidogrel in patients taking different doses of aspirin: results of the interaction trial. Journal of Thrombosis and Haemostasis. 13:347-352. 2015
- Corrigendum. Journal of Thrombosis and Haemostasis. 13:489-489. 2015
- Multiple daily doses of acetyl‐salicylic acid (ASA) overcome reduced platelet response to once‐daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial. Journal of Thrombosis and Haemostasis. 13:448-456. 2015
- Real‐world variability in dabigatran levels in patients with atrial fibrillation. Journal of Thrombosis and Haemostasis. 13:353-359. 2015
- HD1, a thrombin-directed aptamer, binds exosite 1 on prothrombin with high affinity and inhibits its activation by prothrombinase.. Journal of Biological Chemistry. 290:4813-4813. 2015
- Long range communication between exosites 1 and 2 modulates thrombin function.. Journal of Biological Chemistry. 290:4814-4814. 2015
- Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis. New England Journal of Medicine. 372:232-240. 2015
- d-Dimer Testing to Select Patients With a First Unprovoked Venous Thromboembolism Who Can Stop Anticoagulant Therapy. ACP journal club. 162:27-34. 2015
- Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thrombosis and Haemostasis. 114:198-205. 2015
- Edoxaban for treatment of venous thromboembolism in patients with cancer. Thrombosis and Haemostasis. 114:1268-1276. 2015
- Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. Thrombosis and Haemostasis. 114:1113-1126. 2015
- Transition from apixaban to warfarin—addressing excess stroke, systemic embolism, and major bleeding. American Heart Journal. 169:1-3. 2015
- Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Thrombosis and Haemostasis. 114:645-650. 2015
- Vorapaxar, Combination Antiplatelet Therapy, and Stroke∗. Journal of the American College of Cardiology. 64:2327-2329. 2014
- Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents. Journal of Thrombosis and Haemostasis. 12:1810-1815. 2014
- Dabigatran-related coagulopathy: when can we assume the effect has “worn off”?. American Journal of Emergency Medicine. 32:1433-1434. 2014
- Thrombosis. Arteriosclerosis, Thrombosis and Vascular Biology. 34:2363-2371. 2014
- Thrombosis: A major contributor to global disease burden. Thrombosis Research. 134:931-938. 2014
- The Postthrombotic Syndrome: Evidence-Based Prevention, Diagnosis, and Treatment Strategies. Circulation. 130:1636-1661. 2014
- Guidance, guidelines, and communications. Journal of Thrombosis and Haemostasis. 12:1744-1745. 2014
- Plasma fibronectin supports hemostasis and regulates thrombosis. Journal of Clinical Investigation. 124:4281-4293. 2014
- Reduced Plasminogen Binding and Delayed Activation Render γ′-Fibrin More Resistant to Lysis than γA-Fibrin. Journal of Biological Chemistry. 289:27494-27503. 2014
- Thrombosis: A Major Contributor to Global Disease Burden. Seminars in Vascular Medicine. 40:724-735. 2014
- Thrombosis: a major contributor to the global disease burden. Arteriosclerosis, Thrombosis and Vascular Biology. 12:1580-1590. 2014
- Comparison of three‐factor and four‐factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. Journal of Thrombosis and Haemostasis. 12:1428-1436. 2014
- Neutrophil Extracellular Traps Promote Thrombin Generation Through Platelet-Dependent and Platelet-Independent Mechanisms. Arteriosclerosis, Thrombosis and Vascular Biology. 34:1977-1984. 2014
- Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood. 124:1020-1028. 2014
- Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. AIDS. 28:1791-1796. 2014
- Role of phenotypic and genetic testing in managing clopidogrel therapy. Blood. 124:689-699. 2014
- The mTORC Pathway in the Antiphospholipid Syndrome. New England Journal of Medicine. 371:369-371. 2014
- Non-Vitamin K Antagonist Oral Anticoagulants. Chest. 145:1177-1178. 2014
- Periprocedural Management of New Oral Anticoagulants in Patients Undergoing Atrial Fibrillation Ablation. Circulation. 129:1688-1694. 2014
- Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood. 123:2102-2107. 2014
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. The Lancet. 383:955-962. 2014
- Myocardial Injury after Noncardiac Surgery. Anesthesiology. 120:564-578. 2014
- Comparison of the effect of coagulation and platelet function impairments on various mouse bleeding models. Thrombosis and Haemostasis. 112:412-418. 2014
- Expanding use of new oral anticoagulants. F1000Prime Reports. 6:93. 2014
- Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome. Thrombosis and Haemostasis. 112:924-931. 2014
- Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thrombosis and Haemostasis. 112:781-782. 2014
- Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits. Thrombosis and Haemostasis. 112:79-86. 2014
- Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome. Thrombosis and Haemostasis. 111:1141-1152. 2014
- Thrombosis: A major contributor to global disease burden. Thrombosis and Haemostasis. 112:843-852. 2014
- The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligand. BMC Molecular and Cell Biology. 14:6. 2013
- Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine. 369:2093-2104. 2013
- Targeted Gene Sequencing Identifies Variants in the Protein C and Endothelial Protein C Receptor Genes in Patients With Unprovoked Venous Thromboembolism. Arteriosclerosis, Thrombosis and Vascular Biology. 33:2674-2681. 2013
- Zn2+ Mediates High Affinity Binding of Heparin to the αC Domain of Fibrinogen. Journal of Biological Chemistry. 288:29394-29402. 2013
- The Real Decoy. Circulation Research. 113:954-957. 2013
- Four-Factor Prothrombin Complex Concentrate for Urgent Reversal of Vitamin K Antagonists in Patients With Major Bleeding. Circulation. 128:1179-1181. 2013
- Oral Apixaban for the Treatment of Acute Venous Thromboembolism. New England Journal of Medicine. 369:799-808. 2013
- Novel oral anticoagulants in gastroenterology practice. Gastrointestinal Endoscopy. 78:227-239. 2013
- Strain history dependence of the nonlinear stress response of fibrin and collagen networks. Proceedings of the National Academy of Sciences of the United States of America. 110:12197-12202. 2013
- Batroxobin Binds Fibrin with Higher Affinity and Promotes Clot Expansion to a Greater Extent than Thrombin. Journal of Biological Chemistry. 288:16862-16871. 2013
- Extended treatment of venous thromboembolism.. Clinical Advances in Hematology and Oncology. 11:302-304. 2013
- Apixaban for Extended Treatment of Venous Thromboembolism. New England Journal of Medicine. 368:699-708. 2013
- Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?. Journal of Thrombosis and Thrombolysis. 35:295-301. 2013
- Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. Journal of Thrombosis and Haemostasis. 11:245-252. 2013
- Selectived-Dimer Testing for Diagnosis of a First Suspected Episode of Deep Venous Thrombosis. ACP journal club. 158:93-93. 2013
- Dabigatran monitoring made simple?. Thrombosis and Haemostasis. 110:393-395. 2013
- Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies. Thrombosis and Haemostasis. 110:205-212. 2013
- General mechanisms of coagulation and targets of anticoagulants (Section I). Thrombosis and Haemostasis. 109:569-579. 2013
- Genetics of Coagulation: What the Cardiologist Needs to Know. Canadian Journal of Cardiology. 29:75-88. 2013
- Parenteral anticoagulants in heart disease: Current status and perspectives (Section II). Thrombosis and Haemostasis. 109:769-786. 2013
- Procoagulants for management of bleeding with the new oral anticoagulants. Thrombosis and Haemostasis. 110:01-01. 2013
- Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Thrombosis and Haemostasis. 110:1087-1107. 2013
- Zinc: An important cofactor in haemostasis and thrombosis. Thrombosis and Haemostasis. 109:421-430. 2013
- Warfarin After Bioprosthetic Aortic Valve Implantation. Journal of the American Medical Association (JAMA). 308:2147-2147. 2012
- Periprocedural Management and Approach to Bleeding in Patients Taking Dabigatran. Circulation. 126:2428-2432. 2012
- Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo. Acta Biomaterialia. 8:4092-4100. 2012
- By Increasing the Affinity of Heparin for Fibrin, Zn²⁺ Promotes the Formation of a Ternary Heparin–Thrombin–Fibrin Complex That Protects Thrombin from Inhibition by Antithrombin. Biochemistry. 51:7964-7973. 2012
- Modification of Polyurethane with Polyethylene Glycol–Corn Trypsin Inhibitor for Inhibition of Factor Xlla in Blood Contact. Journal of Biomaterials Science, Polymer Edition. 23:1981-1993. 2012
- Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery. 144:944-950.e3. 2012
- Oral Direct Factor Xa Inhibitors. Circulation Research. 111:1069-1078. 2012
- Guided Antithrombotic Therapy: Current Status and Future Research Direction. Circulation. 126:1645-1662. 2012
- Translational Success Stories. Circulation Research. 111:920-929. 2012
- Error in Viewpoint in: Statin Therapy for Healthy Men Identified as ‘Increased Risk,’. Journal of the American Medical Association (JAMA). 307:2590-2590. 2012
- Diannexin, an annexin A5 homodimer, binds phosphatidylserine with high affinity and is a potent inhibitor of platelet‐mediated events during thrombus formation. Journal of Thrombosis and Haemostasis. 10:1109-1119. 2012
- A Protease TAMER: a nucleic acid‐based anticoagulant. Journal of Thrombosis and Haemostasis. 10:867-869. 2012
- Dabigatran and risk of myocardial infarction. Nature Reviews Cardiology. 9:260-262. 2012
- New oral anticoagulants: A view from the laboratory. American Journal of Hematology. 87:S133-S136. 2012
- Dual surface modification with PEG and corn trypsin inhibitor: Effect of PEG:CTI ratio on protein resistance and anticoagulant properties. Journal of Biomedical Materials Research - Part A. 100A:856-862. 2012
- New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes. Journal of the American College of Cardiology. 59:1413-1425. 2012
- More on Acutely Injured Patients Receiving Dabigatran. New England Journal of Medicine. 366:863-864. 2012
- Apixaban versus Enoxaparin in Medically Ill Patients. New England Journal of Medicine. 366:767-768. 2012
- A High Affinity Interaction of Plasminogen with Fibrin Is Not Essential for Efficient Activation by Tissue-type Plasminogen Activator. Journal of Biological Chemistry. 287:4652-4661. 2012
- Antiplatelet Drugs. Chest. 141:e89S-e119S. 2012
- New Antithrombotic Drugs. Chest. 141:e120S-e151S. 2012
- Parenteral Anticoagulants. Chest. 141:e24S-e43S. 2012
- Idrabiotaparinux treatment for venous thromboembolism. The Lancet. 379:96-98. 2012
- New oral anticoagulants: which one should my patient use?. Hematology. American Society of Hematology. Education Program. 2012:536-540. 2012
- Prognostic utility and characterization of cell-free DNA in patients with severe sepsis. Critical Care. 16:R151-R151. 2012
- Should Warfarin Be Restarted After Warfarin-Associated Intracranial Hemorrhage?. Canadian Journal of Cardiology. 28:6-8. 2012
- Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. Blood. 118:6667-6674. 2011
- Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients. New England Journal of Medicine. 365:2167-2177. 2011
- Surface modification with polyethylene glycol–corn trypsin inhibitor conjugate to inhibit the contact factor pathway on blood-contacting surfaces. Acta Biomaterialia. 7:4177-4186. 2011
- Hypercoagulable States. Critical Care Clinics. 27:933-952. 2011
- Histidine-rich Glycoprotein Binds Fibrin(ogen) with High Affinity and Competes with Thrombin for Binding to the γ′-Chain. Journal of Biological Chemistry. 286:30314-30323. 2011
- Importance of Family History as a Risk Factor for Venous Thromboembolism. Circulation. 124:996-997. 2011
- Histidine-rich glycoprotein binds factor XIIa with high affinity and inhibits contact-initiated coagulation. Blood. 117:4134-4141. 2011
- New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty. The BMJ. 342:c7270-c7270. 2011
- Therapeutics New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty. The BMJ. 342. 2011
- Factor Xa and thrombin as targets for new oral anticoagulants. Thrombosis Research. 127:S5-S12. 2011
- Antithrombin-heparin covalent complex reduces microemboli during cardiopulmonary bypass in a pig model. Blood. 116:5716-5723. 2010
- Assays for Measuring Rivaroxaban: Their Suitability and Limitations. Therapeutic Drug Monitoring. 32:673-679. 2010
- Hypercoagulable States. Clinics in Chest Medicine. 31:659-673. 2010
- Antithrombotic Activity of the Novel Oral Anticoagulant, Tecarfarin [Sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in Animal Models. Thrombosis Research. 126:e383-e388. 2010
- Binding of Anti-GRP78 Autoantibodies to Cell Surface GRP78 Increases Tissue Factor Procoagulant Activity via the Release of Calcium from Endoplasmic Reticulum Stores. Journal of Biological Chemistry. 285:28912-28923. 2010
- Factors Associated With Adverse Outcomes in Outpatients Presenting With Pulmonary Embolism. Circulation. Cardiovascular Quality and Outcomes. 3:390-394. 2010
- Meeting the Unmet Needs in Anticoagulant Therapy. European Journal of Haematology, Supplement. 85:1-28. 2010
- New Anticoagulants. Circulation. 121:1523-1532. 2010
- New and Emerging Anticoagulant Therapies for Venous Thromboembolism. Current Treatment Options in Cardiovascular Medicine. 12:142-155. 2010
- Potential of new anticoagulants in patients with cancer. Thrombosis Research. 125:S30-S35. 2010
- Role of the tissue factor pathway in the biology of tumor initiating cells. Thrombosis Research. 125:S44-S50. 2010
- Update on heparin: what do we need to know?. Journal of Thrombosis and Thrombolysis. 29:199-207. 2010
- A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thrombosis and Haemostasis. 104:1150-1157. 2010
- Another oral thrombin inhibitor for stroke prevention in atrial fibrillation?. Thrombosis and Haemostasis. 103:481-483. 2010
- HD1, a thrombin- and prothrombin-binding DNA aptamer, inhibits thrombin generation by attenuating prothrombin activation and thrombin feedback reactions. Thrombosis and Haemostasis. 103:83-96. 2010
- New oral anticoagulants in development. Thrombosis and Haemostasis. 103:62-70. 2010
- Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. Thrombosis and Haemostasis. 104:642-649. 2010
- Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thrombosis and Haemostasis. 104:633-641. 2010
- Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs. Journal of Thrombosis and Thrombolysis. 28:366-380. 2009
- Long Range Communication between Exosites 1 and 2 Modulates Thrombin Function. Journal of Biological Chemistry. 284:25620-25629. 2009
- Otamixaban in acute coronary syndromes. The Lancet. 374:762-764. 2009
- New Antithrombotic Drugs. Clinical Pharmacology and Therapeutics. 86:139-146. 2009
- Prevention and treatment of venous thromboembolism during pregnancy. Catheterization and Cardiovascular Interventions. 74:S22-S26. 2009
- Inferior Vena Cava Ligation Rapidly Induces Tissue Factor Expression and Venous Thrombosis in Rats. Arteriosclerosis, Thrombosis and Vascular Biology. 29:863-869. 2009
- G-Protein–Coupled Receptors as Signaling Targets for Antiplatelet Therapy. Arteriosclerosis, Thrombosis and Vascular Biology. 29:449-457. 2009
- Anticoagulation for ST-Segment Elevation Myocardial Infarction. Circulation. 119:1186-1188. 2009
- Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development. Clinical Pharmacokinetics. 48:1-22. 2009
- Dabigatran etexilate for prevention of venous thromboembolism. Thrombosis and Haemostasis. 101:2-4. 2009
- Leukocyte urokinase plasminogen activator receptor and PSGL1 play a role in endogenous arterial fibrinolysis. Thrombosis and Haemostasis. 102:1212-1218. 2009
- Unanswered questions in venous thromboembolism. Thrombosis Research. 123:S2-S10. 2009
- Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood. 112:4432-4436. 2008
- Inhibition of osteolytic bone metastasis by unfractionated heparin. Clinical and Experimental Metastasis. 25:903-911. 2008
- Contribution of Host-Derived Tissue Factor to Tumor Neovascularization. Arteriosclerosis, Thrombosis and Vascular Biology. 28:1975-1981. 2008
- New antithrombotic drugs (vol 133, pg 234S, 2008). Chest. 134:473-473. 2008
- Parenteral anticoagulants: American college of chest physicians evidence-based clinical practice guidelines (8th edition) (vol 133, pg 141S, 2008). Chest. 134:474-474. 2008
- Selective factor Xa inhibition for thromboprophylaxis. The Lancet. 372:6-8. 2008
- Apixaban (vol 33, pg 293, 2008). Drugs of the Future. 33:556-556. 2008
- New Antithrombotic Drugs. Chest. 133:234S-256S. 2008
- Parenteral Anticoagulants. Chest. 133:141S-159S. 2008
- Apixaban. Drugs of the Future. 33:0293-0293. 2008
- New Anticoagulants for Treatment of Venous Thromboembolism. Arteriosclerosis, Thrombosis and Vascular Biology. 28:380-386. 2008
- Bivalent Binding to γA/γ′-Fibrin Engages Both Exosites of Thrombin and Protects It from Inhibition by the Antithrombin-Heparin Complex. Journal of Biological Chemistry. 283:2470-2477. 2008
- Multimerin 1 binds factor V and activated factor V with high affinity and inhibits thrombin generation. Thrombosis and Haemostasis. 100:1058-1067. 2008
- Elevated tissue factor procoagulant activity in CD133‐positive cancer cells. Journal of Thrombosis and Haemostasis. 5:2550-2552. 2007
- A Replacement for Warfarin. Circulation. 116:131-133. 2007
- Anticoagulants in heart disease: current status and perspectives. European Heart Journal. 28:880-913. 2007
- Emerging Anticoagulant Drugs. Arteriosclerosis, Thrombosis and Vascular Biology. 27:721-721. 2007
- In the Presence of Phospholipids, Glycosaminoglycans Potentiate Factor Xa-Mediated Protein C Activation by Modulating Factor Xa Activity. Biochemistry. 46:4195-4203. 2007
- Beyond heparin and warfarin: the new generation of anticoagulants. Expert Opinion on Investigational Drugs. 16:271-282. 2007
- The role of tumor-and host-related tissue factor pools in oncogene-driven tumor progression. Thrombosis Research. 120:S82-S91. 2007
- Thrombotic Disorders. DeckerMed Transitional Year Weekly Curriculum™. 193-222. 2007
- HD1, a Thrombin-directed Aptamer, Binds Exosite 1 on Prothrombin with High Affinity and Inhibits Its Activation by Prothrombinase. Journal of Biological Chemistry. 281:37477-37485. 2006
- Emerging themes in the treatment of venous thromboembolism. Thrombosis and Haemostasis. 96:239-241. 2006
- OASIS-6: should patients with acute ST-segment elevation myocardial infarction be treated with fondaparinux?. Nature Reviews Cardiology. 3:478-479. 2006
- Heparin Synergistically Enhances Interleukin-11 Signaling through Up-regulation of the MAPK Pathway. Journal of Biological Chemistry. 281:20780-20787. 2006
- The status of new anticoagulants. British Journal of Haematology. 134:3-19. 2006
- An Evaluation of d-Dimer in the Diagnosis of Pulmonary Embolism. ACP journal club. 144:812-812. 2006
- Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes. New England Journal of Medicine. 354:1464-1476. 2006
- Incorporation of Fragment X into Fibrin Clots Renders Them More Susceptible to Lysis by Plasmin. Biochemistry. 45:4257-4265. 2006
- Changing Paradigms in the Management of Venous Thromboembolism. The American heart hospital journal. 4:135-141. 2006
- A non-anticoagulant synthetic pentasaccharide reduces inflammation in a murine model of kidney ischemia-reperfusion injury. Thrombosis and Haemostasis. 96:802-806. 2006
- Emerging anticoagulants for the treatment of venous thromboembolism. Thrombosis and Haemostasis. 96:274-284. 2006
- Emerging themes in the treatment of venous thromboembolism. Thrombosis and Haemostasis. 96:239-241. 2006
- Initial treatment of venous thromboembolism. Thrombosis and Haemostasis. 96:242-250. 2006
- Pharmacology and Clinical Potential of Direct Thrombin Inhibitors. Current Pharmaceutical Design. 11:3877-3884. 2005
- Coagulation Assays. Circulation. 112:e53-e60. 2005
- Emerging therapies for stroke prevention in atrial fibrillation. European Heart Journal, Supplement. 7:C19-C27. 2005
- New anticoagulants: beyond heparin, low‐molecular‐weight heparin and warfarin. British Journal of Pharmacology. 144:1017-1028. 2005
- Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention. Circulation. 111:1390-1397. 2005
- Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 105:1734-1741. 2005
- New Anticoagulant Therapy. Annual Review of Medicine. 56:63-77. 2005
- New anticoagulants. Blood. 105:453-463. 2005
- Heparin compromises streptokinase-induced arterial patency in rabbits. Thrombosis Research. 115:427-434. 2005
- Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood. 104:3958-3964. 2004
- Modes and consequences of thrombin's interaction with fibrin. Biophysical Chemistry. 112:277-284. 2004
- New anticoagulants: an update.. Clinical Advances in Hematology and Oncology. 2:743-749. 2004
- Antithrombotic Therapy During Percutaneous Coronary Intervention. Chest. 126:576S-599S. 2004
- New Anticoagulant Drugs. Chest. 126:265S-286S. 2004
- Management of Venous Thromboembolism: Present and Future. Circulation. 110:I2. 2004
- New Anticoagulants for Treatment of Venous Thromboembolism. Circulation. 110:I19-I26. 2004
- Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. Journal of Thrombosis and Haemostasis. 2:743-749. 2004
- Novel antithrombotic therapies for the prevention of stroke in patients with atrial fibrillation.. American Journal of Managed Care. 10:S72-S82. 2004
- Ximelagatran: the first oral direct thrombin inhibitor. Expert Opinion on Investigational Drugs. 13:403-413. 2004
- Ximelagatran: the first oral direct thrombin inhibitor.. Expert Opinion on Investigational Drugs. 13:403-413. 2004
- Oncogenes as Regulators of Tissue Factor Expression in Cancer: Implications for Tumor Angiogenesis and Anti-Cancer Therapy. Seminars in Vascular Medicine. 30:21-30. 2004
- Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thrombosis and Haemostasis. 91:1090-1096. 2004
- FOREWORD. Drugs. 64:i-ii. 2004
- Localization of heparin and low-molecular-weight heparin in the rat kidney. Thrombosis and Haemostasis. 91:927-934. 2004
- Meeting the Challenges in the Management of Venous Thromboembolism. Oral Direct Thrombin Inhibition: A New Concept - A seminar-in-print - Foreword. Drugs. 64. 2004
- Thrombophilia and New Anticoagulant Drugs. Hematology. American Society of Hematology. Education Program. 2004:424-438. 2004
- An Update on New Anticoagulants. Cardiovascular and Hematological Disorders - Drug Targets. 3:287-300. 2003
- Life-Threatening Thrombosis in Mice With Targeted Arg48-to-Cys Mutation of the Heparin-Binding Domain of Antithrombin. Circulation Research. 93:1120-1126. 2003
- Glycosaminoglycans Bind Factor Xa in a Ca²⁺-Dependent Fashion and Modulate Its Catalytic Activity. Biochemistry. 42:13091-13098. 2003
- Heparin and Angiogenesis. Arteriosclerosis, Thrombosis and Vascular Biology. 23:1954-1955. 2003
- Emerging Anticoagulant Drugs. Arteriosclerosis, Thrombosis and Vascular Biology. 23:1491-1500. 2003
- Mechanism of Catalysis of Inhibition of Factor IXa by Antithrombin in the Presence of Heparin or Pentasaccharide. Journal of Biological Chemistry. 278:35767-35774. 2003
- Neutrophils and the protein C pathway. Blood. 102:1152-1153. 2003
- Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism. New England Journal of Medicine. 349:631-639. 2003
- Bivalirudin, thrombin and platelets: clinical implications and future directions.. Journal of Invasive Cardiology. Suppl:2-15. 2003
- A novel approach to thrombin inhibition. Thrombosis Research. 109:S17-S22. 2003
- Evidence That Both Exosites on Thrombin Participate in Its High Affinity Interaction with Fibrin. Journal of Biological Chemistry. 278:21584-21591. 2003
- Mechanisms Responsible for Catalysis of the Inhibition of Factor Xa or Thrombin by Antithrombin Using a Covalent Antithrombin-Heparin Complex. Journal of Biological Chemistry. 278:23398-23409. 2003
- A Diagnostic Strategy Involving a Quantitative Latex d-Dimer Assay Reliably Excludes Deep Venous Thrombosis. ACP journal club. 138:787-787. 2003
- Heparan sulfate: Antithrombotic or not?. Journal of Clinical Investigation. 111:952-954. 2003
- Heparan sulfate: Antithrombotic or not?. Journal of Clinical Investigation. 111:952-954. 2003
- Thromboprophylaxis in surgical patients.. Canadian Journal of Surgery. 46:129-135. 2003
- The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model. Journal of Thrombosis and Haemostasis. 1:587-594. 2003
- Direct Thrombin Inhibitors in Cardiac Disease. Cardiovascular Toxicology. 3:13-26. 2003
- Evaluation of DNA aptamers directed to thrombin as potential thrombus imaging agents. Nuclear Medicine and Biology. 30:61-72. 2003
- New Anticoagulants. American Journal of Cardiovascular Drugs. 3:201-209. 2003
- New Anticoagulants. Seminars in Vascular Medicine. 29:619-632. 2003
- Orally Active Direct Thrombin Inhibitors. Seminars in Vascular Medicine. 03:131-138. 2003
- Untitled - Response. Circulation. 106:E200-E201. 2002
- Identification of Dp71 Isoforms in the Platelet Membrane Cytoskeleton. Journal of Biological Chemistry. 277:47106-47113. 2002
- Reasons for Resistance to Aspirin in Cardiovascular Disease. Circulation. 106:1-2. 2002
- Reasons for resistance to aspirin in cardiovascular disease.. Circulation. 106:e181-e182. 2002
- Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. European Heart Journal. 23:1771-1779. 2002
- Antithrombin-Independent Anticoagulation by Hypersulfated Low-Molecular-Weight Heparin. Trends in Cardiovascular Medicine. 12:281-287. 2002
- The Lectin-like Domain of Thrombomodulin Confers Protection from Neutrophil-mediated Tissue Damage by Suppressing Adhesion Molecule Expression via Nuclear Factor κB and Mitogen-activated Protein Kinase Pathways. Journal of Experimental Medicine (JEM). 196:565-577. 2002
- In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. Thrombosis Research. 107:241-244. 2002
- Low-dose warfarin in rehabilitating stroke survivors. Thrombosis Research. 107:287-290. 2002
- Antithrombin-Heparin Covalent Complex. Circulation. 106:261-265. 2002
- Direct thrombin inhibitors. Thrombosis Research. 106:V275-V284. 2002
- Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events. Circulation. 105:1650-1655. 2002
- Acute coronary syndromes: a focus on thrombin.. Journal of Invasive Cardiology. 14 Suppl B:2B-7B. 2002
- Incorporation of Vitronectin into Fibrin Clots. Journal of Biological Chemistry. 277:7520-7528. 2002
- Vimentin Exposed on Activated Platelets and Platelet Microparticles Localizes Vitronectin and Plasminogen Activator Inhibitor Complexes on Their Surface. Journal of Biological Chemistry. 277:7529-7539. 2002
- Direct Thrombin Inhibitors in Acute Coronary Syndromes. Circulation. 105:1004-1011. 2002
- Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. The Lancet. 359:294-302. 2002
- Conformational Changes in Thrombin When Complexed by Serpins. Journal of Biological Chemistry. 276:44828-44834. 2001
- Utility of ultrasound imaging of the lower extremities in the diagnostic approach in patients with suspected pulmonary embolism. Journal of Internal Medicine. 250:262-264. 2001
- Characterization of a Mouse Model for Thrombomodulin Deficiency. Arteriosclerosis, Thrombosis and Vascular Biology. 21:1531-1537. 2001
- Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: Results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis). American Heart Journal. 142:237-243. 2001
- Management of Suspected Deep Venous Thrombosis in Outpatients by Using Clinical Assessment and d-dimer Testing. ACP journal club. 135:108-108. 2001
- Molecular Basis for the Susceptibility of Fibrin-bound Thrombin to Inactivation by Heparin Cofactor II in the Presence of Dermatan Sulfate but Not Heparin. Journal of Biological Chemistry. 276:20959-20965. 2001
- Recruiting researchers.. Clinical and Investigative Medicine. 24:159. 2001
- Hypersulfated Low Molecular Weight Heparin with Reduced Affinity for Antithrombin Acts as an Anticoagulant by Inhibiting Intrinsic Tenase and Prothrombinase. Journal of Biological Chemistry. 276:9755-9761. 2001
- Use of a Fixed Activated Partial Thromboplastin Time Ratio to Establish a Therapeutic Range for Unfractionated Heparin. JAMA Internal Medicine. 161:385-385. 2001
- Prognostic Significance of Thrombocytopenia During Hirudin and Heparin Therapy in Acute Coronary Syndrome Without ST Elevation. Circulation. 103:643-650. 2001
- Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. Journal of the American College of Cardiology. 37:475-484. 2001
- Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention. Chest. 119:321S-336S. 2001
- Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest. 119:321S-336S. 2001
- Fibrinolytic Variables in Patients with Recurrent Venous Thrombosis: a Prospective Cohort Study. Thrombosis and Haemostasis. 85:390-394. 2001
- Like Fibrin, (DD)E, the Major Degradation Product of Crosslinked Fibrin, Protects Plasmin from Inhibition by α2-antiplasmin. Thrombosis and Haemostasis. 85:502-508. 2001
- New Anticoagulant Drugs. Chest. 119:95S-107S. 2001
- New anticoagulant drugs. Chest. 119:95S-107S. 2001
- New anticoagulant drugs.. Journal of Thrombosis and Thrombolysis. 12:7-17. 2001
- Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.. Journal of Invasive Cardiology. 12 Suppl F:14F-149. 2000
- Cardiac myocytes, an inducible source of tissue type plasminogen activator production: potential implications in fibrinolysis and wound healing following myocardial infarction. Blood. 96. 2000
- Hemorrhagic complications in association with percutaneous coronary intervention: can the risk be attenuated?. Journal of Invasive Cardiology. 12 Suppl F:7F-13. 2000
- Identification of the mechanism responsible for the decreased fibrin specificity of reteplase relative to tissue-type plasminogen activator. Blood. 96. 2000
- Incorporation of fragment x into clots increases their susceptibility to lysis. Blood. 96. 2000
- Phospholipid micelles, but not vesicles, neutralize heparin: an explanation for the minimal effect of heparin on the prothrombin time. Blood. 96. 2000
- Putting heparin into perspective: its history and the evolution of its use during percutaneous coronary interventions.. Journal of Invasive Cardiology. 12 Suppl F:20F-206. 2000
- The mechanism of action of thrombin inhibitors.. Journal of Invasive Cardiology. 12 Suppl F:27F-232. 2000
- Treatment of Proximal Deep Vein Thrombosis With a Novel Synthetic Compound (SR90107A/ORG31540) With Pure Anti–Factor Xa Activity. Circulation. 102:2726-2731. 2000
- Safety of Withholding Heparin in Pregnant Women with a History of Venous Thromboembolism. New England Journal of Medicine. 343:1439-1444. 2000
- Dalteparin for unstable angina and non-Q-wave myocardial infarction - In reply. Archives of Internal Medicine. 160:3170-3170. 2000
- Thrombin-activable Fibrinolysis Inhibitor Attenuates (DD)E-mediated Stimulation of Plasminogen Activation by Reducing the Affinity of (DD)E for Tissue Plasminogen Activator. Journal of Biological Chemistry. 275:36612-36620. 2000
- Management of unstable angina and myocardial infarction. The Lancet. 356:1193-1194. 2000
- Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. European Heart Journal. 21:1473-1481. 2000
- Type 1 Plasminogen Activator Inhibitor Binds to Fibrin via Vitronectin. Journal of Biological Chemistry. 275:19788-19794. 2000
- Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. The Lancet. 355:1936-1942. 2000
- Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood. Nuclear Medicine and Biology. 27:289-297. 2000
- Identification of the Mechanism Responsible for the Increased Fibrin Specificity of TNK-Tissue Plasminogen Activator Relative to Tissue Plasminogen Activator. Journal of Biological Chemistry. 275:10112-10120. 2000
- Beyond Heparin and Aspirin. JAMA Internal Medicine. 160:749-749. 2000
- Erratum: Sensitivity and specificity of a rapid whole-blood assay for D- dimer in the diagnosis of pulmonary embolism (Annals of Internal Medicine (1998) 129 (1006-1011)). Annals of Internal Medicine. 132:247. 2000
- Sensitivity and specificity of a rapid whole-blood assay for D-dimer in the diagnosis of pulmonary embolism (vol 129, pg 1006, 1998). Annals of Internal Medicine. 132:247-247. 2000
- The Asp272–Glu282 Region of Platelet Glycoprotein Ibα Interacts with the Heparin-binding Site of α-Thrombin and Protects the Enzyme from the Heparin-catalyzed Inhibition by Antithrombin III. Journal of Biological Chemistry. 275:3887-3895. 2000
- Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. Hematology. American Society of Hematology. Education Program. 2000:266-284. 2000
- Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer. Thrombosis and Haemostasis. 83:416-420. 2000
- Identification of a Unique Glomerular Factor X Activator in Murine Lupus Nephritis. Journal of the American Society of Nephrology. 10:2332-2341. 1999
- Thrombosis and anticoagulation. Seminars in Hematology. 36:118-132. 1999
- Thrombosis and anticoagulation.. Seminars in Hematology. 36:118-132. 1999
- Clinical Utility of a Rapid Whole-Bloodd-Dimer Assay in Patients with Cancer Who Present with Suspected Acute Deep Venous Thrombosis. ACP journal club. 131:417-417. 1999
- Comparison of Heparin- and Dermatan Sulfate-mediated Catalysis of Thrombin Inactivation by Heparin Cofactor II. Journal of Biological Chemistry. 274:27597-27604. 1999
- Homocysteine-Induced Endoplasmic Reticulum Stress and Growth Arrest Leads to Specific Changes in Gene Expression in Human Vascular Endothelial Cells. Blood. 94:959-967. 1999
- Erratum: New antithrombotic agents (The Lancet (1999) April 24 (1431)). The Lancet. 353:1804. 1999
- New antithrombotic agents (vol 353, pg 1431, 1999). The Lancet. 353:1804-1804. 1999
- Structure-Function Analyses of Thrombomodulin by Gene-Targeting in Mice: The Cytoplasmic Domain Is Not Required for Normal Fetal Development. Blood. 93:3442-3450. 1999
- New antithrombotic agents. The Lancet. 353:1431-1436. 1999
- A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous Thromboembolism. New England Journal of Medicine. 340:901-907. 1999
- Deep vein thrombosis. Current Treatment Options in Cardiovascular Medicine. 1:43-53. 1999
- Exosites 1 and 2 Are Essential for Protection of Fibrin-bound Thrombin from Heparin-catalyzed Inhibition by Antithrombin and Heparin Cofactor II. Journal of Biological Chemistry. 274:6226-6233. 1999
- A Histomorphometric Evaluation of Heparin-Induced Bone Loss After Discontinuation of Heparin Treatment in Rats. Blood. 93:1231-1236. 1999
- Vasoflux, a New Anticoagulant With a Novel Mechanism of Action. Circulation. 99:682-689. 1999
- Prevention of activation of blood coagulation during acute coronary ischemic syndromes beyond aspirin and heparin. Cardioscience. 41:418-432. 1999
- Mechanism of Action of Plasminogen Activators. Thrombosis and Haemostasis. 82:974-982. 1999
- New Antithrombotic Drugs: Beyond Aspirin and Heparin. Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 29:68-68. 1999
- Sensitivity and Specificity of a Rapid Whole-Blood Assay for D-Dimer in the Diagnosis of Pulmonary Embolism. ACP journal club. 129:1006-1006. 1998
- Use of a Clinical Model for Safe Management of Patients with Suspected Pulmonary Embolism. ACP journal club. 129:997-997. 1998
- Detection of SYT–SSX1/2 fusion transcripts by reverse transcriptase–polymerase chain reaction (RT–PCR) is a valuable diagnostic tool in synovial sarcoma. European Journal of Cancer. 34:2087-2093. 1998
- Investigation of the Anticoagulant Mechanisms of a Covalent Antithrombin-Heparin Complex. Journal of Biological Chemistry. 273:34730-34736. 1998
- Antithrombotic Therapy in Patients Undergoing Coronary Angioplasty. Chest. 114:728S-741S. 1998
- Antithrombotic therapy in patients undergoing coronary angioplasty. Chest. 114:728S-741S. 1998
- Homocysteine-dependent Alterations in Mitochondrial Gene Expression, Function and Structure. Journal of Biological Chemistry. 273:30808-30817. 1998
- New Antithrombotic Agents. Chest. 114:715S-727S. 1998
- New antithrombotic agents. Chest. 114:715S-727S. 1998
- A novel antithrombin-heparin covalent complex. Blood Coagulation and Fibrinolysis. 9:587-596. 1998
- Long-Term Oral Anticoagulant Therapy in Patients With Unstable Angina or Suspected Non–Q-Wave Myocardial Infarction. Circulation. 98:1064-1070. 1998
- Hirudin causes more bleeding than heparin in a rabbit ear bleeding model. Translational Research. 132:181-185. 1998
- Analysis of FUS-CHOP fusion transcripts in different types of soft tissue liposarcoma and their diagnostic implications.. Clinical Cancer Research. 4:1779-1784. 1998
- Characterization of the Interactions of Plasminogen and Tissue and Vampire Bat Plasminogen Activators with Fibrinogen, Fibrin, and the Complex of d-Dimer Noncovalently Linked to Fragment E. Journal of Biological Chemistry. 273:18292-18299. 1998
- Characterization of the stress-inducing effects of homocysteine. Biochemical Journal. 332:213-221. 1998
- Localization of the Thrombin-binding Domain on Prothrombin Fragment 2. Journal of Biological Chemistry. 273:8932-8939. 1998
- Low-Molecular-Weight Heparins. New England Journal of Medicine. 338:687-688. 1998
- Low-molecular-weight heparins - reply. New England Journal of Medicine. 338:687-688. 1998
- Thrombin Binds to Soluble Fibrin Degradation Products Where it Is Protected From Inhibition by Heparin-Antithrombin but Susceptible to Inactivation by Antithrombin-Independent Inhibitors. Circulation. 97:544-552. 1998
- The new heparins. Coronary Artery Disease. 9:65-74. 1998
- A simple clinical model for the diagnosis of deep‐vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process. Journal of Internal Medicine. 243:15-23. 1998
- The Effects of Standard and Low Molecular Weight Heparin on Bone Nodule Formation In Vitro. Thrombosis and Haemostasis. 80:413-417. 1998
- The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearance. Translational Research. 130:649-655. 1997
- Low-molecular-weight heparins (vol 337, pg 688, 1997). New England Journal of Medicine. 337:1567-1567. 1997
- Evidence for Allosteric Linkage between Exosites 1 and 2 of Thrombin. Journal of Biological Chemistry. 272:25493-25499. 1997
- Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism. New England Journal of Medicine. 337:657-662. 1997
- Low-Molecular-Weight Heparins. New England Journal of Medicine. 337:688-698. 1997
- Comparison of the Effects of Two Doses of Recombinant Hirudin Compared With Heparin in Patients With Acute Myocardial Ischemia Without ST Elevation. Circulation. 96:769-777. 1997
- Synthesis and radioiodination of a stannyl oligodeoxyribonucleotide. Nucleic Acids Research (NAR). 25:2897-2901. 1997
- The use of D-dimer testing and impedance plethysmographic examination in patients with clinical indications of deep vein thrombosis. JAMA Internal Medicine. 157:1077-1081. 1997
- A Histomorphometric Comparison of the Effects of Heparin and Low-Molecular-Weight Heparin on Cancellous Bone in Rats. Blood. 89:3236-3242. 1997
- Effect of Nonspecific Binding to Plasma Proteins on the Antithrombin Activities of Unfractionated Heparin, Low-Molecular-Weight Heparin, and Dermatan Sulfate. Circulation. 95:118-124. 1997
- Molecular Basis for the Resistance of Fibrin-Bound Thrombin to Inactivation by Heparin/Serpin Complexes. Advances in Experimental Medicine and Biology. 425:55-66. 1997
- New Concepts in Coagulation. Critical Reviews in Clinical Laboratory Sciences. 34:475-501. 1997
- Diagnosis and Treatment of Chronic Arterial Insufficiency of the Lower Extremities: A Critical Review. Circulation. 94:3026-3049. 1996
- Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood. 88:1314-1320. 1996
- An oral ivermectin regimen that eradicates pinworms (Syphacia spp.) in laboratory rats and mice.. Comparative Medicine. 46:286-290. 1996
- Biologic rationale for the therapeutic role of specific antithrombins. Coronary Artery Disease. 7:409-419. 1996
- Interaction of low molecular weight heparin with ketorolac. Translational Research. 127:583-587. 1996
- Decreased Thrombin Activity of Fibrin Clots Prepared in Cord Plasma Compared with Adult Plasma. Pediatric Research. 39:826-830. 1996
- Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery. JAMA Internal Medicine. 156:851-856. 1996
- A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein Thrombosis. New England Journal of Medicine. 334:677-681. 1996
- Elevated Fibrinopeptide A and B Levels during Thrombolytic Therapy: Real or Artefactual?. Thrombosis and Haemostasis. 75:529-535. 1996
- Evaluation of a Soluble Fibrin Assay in Patients with Suspected Pulmonary Embolism. Thrombosis and Haemostasis. 75:551-554. 1996
- Free Protein S Deficiency May Be Found in Patients with Antiphospholipid Antibodies who Do not Have Systemic Lupus Erythematosus. Thrombosis and Haemostasis. 76:689-691. 1996
- Lysis of surface-localized fibrin clots by adsorbed plasminogen in the presence of tissue plasminogen activator. Clinical Materials. 17:75-77. 1996
- More Effective Suppression of Hemostatic System Activation in Patients Undergoing Cardiac Surgery by Heparin Dosing Based on Heparin Blood Concentrations rather than ACT. Thrombosis and Haemostasis. 76:0902-0908. 1996
- Limited Fibrin Specificity of Tissue-type Plasminogen Activator and Its Potential Link to Bleeding. Journal of Vascular and Interventional Radiology. 6:19S-23S. 1995
- Antithrombotic Therapy in Patients Undergoing Coronary Angioplasty. Chest. 108:486S-501S. 1995
- New Antithrombotics. Chest. 108:471S-485S. 1995
- Collaborative cardiovascular clinical trials in Canada. The Canadian Cardiovascular Collaboration.. Canadian Journal of Cardiology. 11:649-657. 1995
- FIBRIN CLOT LYSIS BY TISSUE PLASMINOGEN ACTIVATOR (tPA) IS IMPAIRED IN PLASMA FROM PEDIATRIC PATIENTS UNDERGOING ORTHOTOPIC LIVER TRANSPLANTATION. Transplantation. 60:144-146. 1995
- New Anticoagulants Hirudin and Hirulog in the Treatment of Acute Coronary Syndromes. Cardiology in Review. 3:196-204. 1995
- Accuracy of clinical assessment of deep-vein thrombosis. The Lancet. 345:1326-1330. 1995
- A Novel and Rapid Whole-Blood Assay for D-Dimer in Patients With Clinically Suspected Deep Vein Thrombosis. Circulation. 91:2184-2187. 1995
- ROUND-TABLE DISCUSSION. American Journal of Cardiology. 75:B93-B97. 1995
- Activation of blood coagulation by plaque rupture: Mechanisms and prevention. American Journal of Cardiology. 75:18B-22B. 1995
- Advances in Antithrombotic Therapy: Novel Agents. Thrombosis and Haemostasis. 74:565-571. 1995
- Comparison of the Accuracy of Impedance Plethysmography and Compression Ultrasonography in Outpatients with Clinically Suspected Deep Vein Thrombosis. Thrombosis and Haemostasis. 74:1423-1427. 1995
- Optimal Duration of Oral Anticoagulant Therapy: A Randomized Trial Comparing Four Weeks with Three Months of Warfarin in Patients with Proximal Deep Vein Thrombosis. Thrombosis and Haemostasis. 74:606-611. 1995
- Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery.. Circulation. 90:2385-2389. 1994
- New Anticoagulant Strategies. Drugs. 48:485-497. 1994
- Interactions of plasminogen and fibrinogen with model silica glass surfaces: Adsorption from plasma and enzymatic activity studies. Journal of applied biomaterials. 28:407-415. 1994
- A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. JAMA Internal Medicine. 154:49-56. 1994
- Effects on Thrombin Generation of Single Injections of Hirulog™ in Patients with Calf Vein Thrombosis. Thrombosis and Haemostasis. 72:523-525. 1994
- Ex-Vivo and In-Vitro Evidence that Low Molecular Weight Heparins Exhibit Less Binding to Plasma Proteins than Unfractionated Heparin. Thrombosis and Haemostasis. 71:300-304. 1994
- New anticoagulant strategies.. Translational Research. 122:364-373. 1993
- Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state [see comments]. Blood. 81:2958-2963. 1993
- Activated platelets form protected zones of adhesion on fibrinogen and fibronectin-coated surfaces.. Journal of Cell Biology. 121:945-955. 1993
- Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis.. Journal of Clinical Investigation. 91:1343-1350. 1993
- Comparison of the Non-Specific Binding of Unfractionated Heparin and Low Molecular Weight Heparin (Enoxaparin) to Plasma Proteins. Thrombosis and Haemostasis. 70:625-630. 1993
- Do Coagulation Screening Tests Detect Increased Generation of Thrombin and Plasmin in Sick Newborn Infants?. Thrombosis and Haemostasis. 69:418-421. 1993
- Limitations of Impedance Plethysmography in the Diagnosis of Clinically Suspected Deep-Vein Thrombosis. ACP journal club. 118:25-25. 1993
- The Additive Effect of Low Molecular Weight Heparins on Thrombin Inhibition by Dermatan Sulfate. Thrombosis and Haemostasis. 70:443-447. 1993
- The Effect of Antithrombin III-Independent Thrombin Inhibitors and Heparin on Fibrin Accretion onto Fibrin-Coated Polyethylene \textbar Request PDF. Thrombosis and Haemostasis. 69:130-134. 1993
- Interactions of thermally denatured fibrinogen on polyethylene with plasma proteins and platelets. Journal of applied biomaterials. 26:1651-1663. 1992
- The Role of Protected Extracellular Compartments in Interactions between Leukocytes, and Platelets, and Fibrin/Fibrinogen Matricesa. Annals of the New York Academy of Sciences. 667:163-172. 1992
- Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin. Blood. 80:960-965. 1992
- THROMBIN ANTITHROMBIN-III COMPLEX-FORMATION IN THE NEONATAL RESPIRATORY-DISTRESS SYNDROME. American Review of Respiratory Disease. 145:767-770. 1992
- Thrombin/Antithrombin III Complex Formation in the Neonatal Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine. 145:767-770. 1992
- Plasma levels of elastase-specific fibrinopeptides correlate with proteinase inhibitor phenotype. Evidence for increased elastase activity in subjects with homozygous and heterozygous deficiency of alpha 1-proteinase inhibitor.. Journal of Clinical Investigation. 89:766-773. 1992
- Antithrombins: Their Potential as Antithrombotic Agents. Annual Review of Medicine. 43:9-16. 1992
- Antithrombins: Their Potential As Antithrombotic Agents. Annual Review of Medicine. 43:9-16. 1992
- Fibrin Clot Lysis by Thrombolytic Agents Is Impaired in Newborns due to a Low Plasminogen Concentration. Thrombosis and Haemostasis. 68:325-330. 1992
- Measurement of Markers of Activated Coagulation in Antithrombin III Deficient Subjects. Thrombosis and Haemostasis. 67:542-544. 1992
- The Effect of Thrombin Inhibitors on Tissue Plasminogen Activator Induced Thrombolysis in a Rat Model. Thrombosis and Haemostasis. 68:064-068. 1992
- The rate of fibrinopeptide B release modulates the rate of clot formation: a study with an acquired inhibitor to fibrinopeptide B release. British Journal of Haematology. 79:296-301. 1991
- Development and Application of Assays for Elastase‐Specific Fibrinogen Fragments^a. Annals of the New York Academy of Sciences. 624:154-166. 1991
- Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.. Journal of Clinical Investigation. 87:1082-1090. 1991
- CD11c/CD18 on neutrophils recognizes a domain at the N terminus of the A alpha chain of fibrinogen.. Proceedings of the National Academy of Sciences of the United States of America. 88:1044-1048. 1991
- Standard and Low Molecular Weight Heparin Have no Effect on Tissue Plasminogen Activator Induced Plasma Clot Lysis or Fibrinogenolysis. Thrombosis and Haemostasis. 65:541-544. 1991
- A Randomized Trial of a Single Bolus Dosage Regimen of Recombinant Tissue Plasminogen Activator in Patients with Acute Pulmonary Embolism. Chest. 98:1473-1479. 1990
- Pulmonary surfactant-associated protein A enhances the surface activity of lipid extract surfactant and reverses inhibition by blood proteins in vitro. Biochemistry. 29:8424-8429. 1990
- Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.. Journal of Clinical Investigation. 86:385-391. 1990
- 6 Mechanism of action of the thrombolytic agents. Best Practice and Research in Clinical Haematology. 3:583-599. 1990
- Urokinase has direct catalytic activity against fibrinogen and renders it less clottable by thrombin.. Journal of Clinical Investigation. 86:203-212. 1990
- A NEW SHORT INFUSION DOSAGE REGIMEN OF RECOMBINANT TISSUE PLASMINOGEN-ACTIVATOR IN PATIENTS WITH VENOUS THROMBOEMBOLIC DISEASE. Chest. 97:S168-S171. 1990
- A New Short Infusion Dosage Regimen of Recombinant Tissue Plasminogen Activator in Patients with Venous Thromboembolic Disease. Chest. 97:168S-171S. 1990
- Effect of Fibrinogen Degradation Products and Lung Ground Substance on Surfactant Function. Neonatology. 57:325-333. 1990
- Use of a synthetic homologue of human fibrinopeptide A for production of a monoclonal antibody specific for the free peptide. Blood. 74:1036-1044. 1989
- Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen.. Journal of Clinical Investigation. 82:1700-1707. 1988
- Complement receptor type three (CD11b/CD18) of human polymorphonuclear leukocytes recognizes fibrinogen.. Proceedings of the National Academy of Sciences of the United States of America. 85:7734-7738. 1988
- Complications of long‐term anticoagulation. Annals of Neurology. 23:570-574. 1988
- Elastase-mediated fibrinogenolysis by chemoattractant-stimulated neutrophils occurs in the presence of physiologic concentrations of antiproteinases.. Journal of Experimental Medicine (JEM). 166:1836-1850. 1987
- Evolution of Thrombosis. Annals of the New York Academy of Sciences. 516:586-604. 1987
- Dysfibrinogenemia in Obstructive Liver Disease. Journal of Pediatric Gastroenterology and Nutrition. 6:967-970. 1987
- Increased Neutrophil Elastase Activity in Cigarette Smokers. ACP journal club. 107:680-680. 1987
- Development of an assay for in vivo human neutrophil elastase activity. Increased elastase activity in patients with alpha 1-proteinase inhibitor deficiency.. Journal of Clinical Investigation. 78:155-162. 1986
- Development of a radioimmunoassay for the fibrinogen-derived peptide B beta 1-42. Blood. 67:1014-1022. 1986
- Effects of Intermittent Pneumatic Calf Compression On Postoperative Thrombin and Plasmin Activity. Thrombosis and Haemostasis. 56:198-201. 1986
- Immunologic Identification of the Cleavage Products from the Aα- and Bβ-Chains in the Early Stages of Plasmin Digestion of Fibrinogen. Thrombosis and Haemostasis. 56:100-106. 1986
- Fibrinogen proteolysis and platelet alpha-granule release in preeclampsia/eclampsia. Blood. 63:525-531. 1984